[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 50 of about 50
1. Caldarelli C, Iacconi C, Della Giovampaola C, Iacconi P, Beatrice F: Vagal paragangliomas: two case reports. Acta Otorhinolaryngol Ital; 2007 Jun;27(3):139-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first patient underwent surgery for suspected carotid body tumour.
  • In the second patient, computed tomography scan and digital angiography allowed a correct pre-operative diagnosis to be made.
  • Histological benign features, absence of neurological symptoms, of local invasion or intracranial extension confirm the frequent benign behaviour of these neoplasms.
  • Contrast computed tomography and digital angiography still remain the gold standard reliable instruments for diagnosis despite the success of magnetic resonance imaging, magnetic resonance angiography and octreotide scintigraphy to detect head and neck paragangliomas.
  • A transcervical approach, without mandibulotomy, is suitable too for large tumours but complete removal, with sparing of involved segments of the vagus nerve, is rarely possible.
  • [MeSH-major] Paraganglioma / pathology. Peripheral Nervous System Neoplasms / pathology. Vagus Nerve / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Maxillofac Surg. 2002 Jun;31(3):334-6 [12190144.001]
  • [Cites] Oral Oncol. 2004 Jul;40(6):563-75 [15063383.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Apr;130(4):479-82 [15100648.001]
  • [Cites] Am J Otolaryngol. 2004 Jul-Aug;25(4):295-300 [15239042.001]
  • [Cites] Ann Surg. 1970 Aug;172(2):246-55 [4317457.001]
  • [Cites] Arch Otolaryngol. 1976 Oct;102(10):534-6 [184772.001]
  • [Cites] Arch Otolaryngol. 1977 Feb;103(2):87-9 [189740.001]
  • [Cites] Laryngoscope. 1977 Aug;87(8):1259-69 [196145.001]
  • [Cites] Laryngoscope. 1980 Oct;90(10 Pt 1):1604-11 [6252396.001]
  • [Cites] N Y State J Med. 1980 Sep;80(10):1567-75 [6252521.001]
  • [Cites] Cancer. 1981 Dec 15;48(12):2717-23 [7306926.001]
  • [Cites] Ear Nose Throat J. 1985 Apr;64(4):190-5 [3996267.001]
  • [Cites] Am J Med. 1985 Jun;78(6 Pt 1):1017-24 [4014261.001]
  • [Cites] Laryngoscope. 1986 May;96(5):533-6 [3010016.001]
  • [Cites] AJNR Am J Neuroradiol. 1986 Sep-Oct;7(5):943-52 [3096120.001]
  • [Cites] Otolaryngol Clin North Am. 1986 Nov;19(4):755-67 [3797012.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1989 Jan;98(1 Pt 1):21-6 [2535921.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Apr;116(4):447-53 [2317327.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2224-8 [2224778.001]
  • [Cites] J Postgrad Med. 1991 Jan;37(1):56-8, 58A [1941697.001]
  • [Cites] Laryngoscope. 1994 Apr;104(4):440-5 [8164483.001]
  • [Cites] Minerva Chir. 1993 Dec;48(23-24):1449-53 [8177450.001]
  • [Cites] Auris Nasus Larynx. 1994;21(2):122-5 [7993226.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Oct;124(10):1133-40 [9776192.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Apr;122(4):482-7 [10740165.001]
  • [Cites] Radiology. 2000 Apr;215(1):237-42 [10751493.001]
  • (PMID = 17883192.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2640040
  •  go-up   go-down


2. Kopelman D, Inbar Y, Hanannel A, Dank G, Freundlich D, Perel A, Castel D, Greenfeld A, Salomon T, Sareli M, Valeanu A, Papa M: Magnetic resonance-guided focused ultrasound surgery (MRgFUS). Four ablation treatments of a single canine hepatocellular adenoma. HPB (Oxford); 2006;8(4):292-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Canine hepatocellular adenomas are benign, well-differentiated, primary hepatic tumors.
  • The aim of this study was to evaluate the safety, accuracy and efficacy of non-invasive focal ablation of tissue volumes of a canine benign liver tumour by consecutive MRgFUS sonications.
  • MATERIALS AND METHODS: Four MRgFUS procedures were performed in a 10-year-old, male, mixed large breed dog (45 kg) under general anaesthesia.
  • Different areas were chosen within the tumour.
  • The tumour was resected and histopathologically examined.
  • RESULTS: The MRgFUS created necrosis with contiguous areas of complete tissue destruction within the liver tumour, in full accordance with the planning.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Ultrasound. 1999 Mar;9(1):11-8 [10099162.001]
  • [Cites] Ultrasound Med Biol. 1999 Jun;25(5):847-56 [10414902.001]
  • [Cites] Med Phys. 1999 Sep;26(9):2017-26 [10505893.001]
  • [Cites] Radiology. 2001 Apr;219(1):176-85 [11274554.001]
  • [Cites] Abdom Imaging. 2001 Jul-Aug;26(4):369-74 [11441548.001]
  • [Cites] Ultrasound Med Biol. 2001 Aug;27(8):1099-106 [11527596.001]
  • [Cites] Cancer J. 2002 May-Jun;8 Suppl 1:S100-12 [12075696.001]
  • [Cites] Radiology. 2002 Nov;225(2):367-77 [12409568.001]
  • [Cites] Radiology. 2003 Mar;226(3):897-905 [12616023.001]
  • [Cites] Radiology. 2003 Jun;227(3):849-55 [12714680.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1240-3 [14515293.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S242-7 [15508090.001]
  • [Cites] Ann Surg Oncol. 2004 Dec;11(12):1061-9 [15545506.001]
  • [Cites] Arch Surg. 1991 Aug;126(8):1002-9; discussion 1009-10 [1863205.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):787-800 [6547421.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 1995 Mar;25(2):419-35 [7785172.001]
  • [Cites] Hepatology. 1995 Mar;21(3):832-6 [7875681.001]
  • [Cites] Invest Radiol. 1994 Mar;29(3):345-51 [8175310.001]
  • [Cites] Adv Surg. 1993;26:189-208 [8418563.001]
  • [Cites] Br J Hosp Med. 1995 Oct 18-31;54(8):378-81 [8535588.001]
  • [Cites] World J Surg. 1995 Nov-Dec;19(6):801-6 [8553669.001]
  • [Cites] Surg Laparosc Endosc. 1995 Dec;5(6):444-9 [8611989.001]
  • (PMID = 18333139.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2023899
  •  go-up   go-down


3. Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM: Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol Oncol; 2007 Dec;1(3):321-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, we presented evidence--based on the analysis of benign hyperproliferative lesions of the breast--for the presence of cells that express the stem cell marker cytokeratin (CK) 15 in combination with CK19, a protein widely expressed by mammary epithelial cells.
  • CK15 expressing tumors constituted 5% (6 out of 120; 4 of ductal type and 2 of lobular type) of the high-risk breast carcinomas examined by gel-based proteomics and immunohistochemistry.
  • The remaining tumor was mainly composed of cells expressing both CK15 and CK19 (CK15+/CK19+), but it also contained invasive areas with cells expressing only one of these makers (CK15+/CK19- and CK15-/CK19+ cells).
  • To address the relationship between putative luminal progenitor/amplified CK15+ cells and malignant disease, and to determine whether cells/lesions lose expression of CK15 as a result of tumour initiation and/or progression, we searched among our sample set for carcinomas in which invasive tumor areas co-existed with non-malignant cells and hyperproliferative and known pre-malignant lesions.
  • Only one such tumour was found (T71), a CK15-/CK19+/p53+ carcinoma that contained p53 negative non-malignant epithelial cells exhibiting a variety of, CK15/CK19 cellular phenotypes (CK15+/CK19+; CK15+/CK19-; CK15-/CK19+; CK15-/CK19-), often associated with simple columnar cells.
  • Cells with a very similar phenotype to the CK15+/CK19+ progenitor cells were observed in a juvenile fibroadenoma as well as in the large collecting ducts of the breast.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Keratin-15 / metabolism. Precancerous Conditions / pathology. Stem Cells
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Female. Fluorescent Antibody Technique, Direct. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness


Advertisement
4. Thamboo TP, Sim R, Tan SY, Yap WM: Primary retroperitoneal mucinous cystadenocarcinoma in a male patient. J Clin Pathol; 2006 Jun;59(6):655-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 64-year-old man presented with a large retroperitoneal cystic tumour measuring 24 x 20 x 16 cm3, which was removed intact.
  • Areas ranging from a benign mucinous cyst to borderline mucinous tumour to mucinous cystadenocarcinoma were observed on microscopy.
  • Strong patchy staining for cytokeratins 7 and 20 and strong diffuse staining for MUC2 and MUC5AC core peptides, similar to staining patterns in ovarian mucinous tumours, were shown in the benign and atypical epithelium.
  • The theory of its origin from the mucinous metaplasia of peritoneal (mesothelial) inclusion cysts, rather than from ectopic ovarian tissue or ovarian teratomas, is supported by the occurrence of such a tumour in a male patient.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Humans. Keratins / metabolism. Male. Middle Aged. Mucins / metabolism. Neoplasm Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jun;31(6):672-7 [10872659.001]
  • [Cites] Arch Pathol Lab Med. 2001 May;125(5):691-4 [11300948.001]
  • [Cites] Surg Today. 2001;31(8):747-50 [11510618.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):391-400 [12352188.001]
  • [Cites] Hinyokika Kiyo. 2003 Mar;49(3):145-7 [12728527.001]
  • [Cites] Gynecol Oncol. 1991 Jul;42(1):64-7 [1717354.001]
  • [Cites] APMIS. 1991 Nov;99(11):1055-7 [1958350.001]
  • [Cites] Acta Cytol. 1994 Mar-Apr;38(2):261-6 [8147222.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):364-72 [8163269.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):308-12 [7959300.001]
  • [Cites] Virchows Arch. 1994;424(1):53-7 [7981904.001]
  • [Cites] Eur J Surg. 1991 Oct;157(10):621-2 [1687258.001]
  • [Cites] Virchows Arch. 1995;426(6):641-5 [7655747.001]
  • [Cites] Clin Imaging. 1996 Apr-Jun;20(2):129-32 [8744823.001]
  • [Cites] J Pathol. 1997 Aug;182(4):385-91 [9306958.001]
  • (PMID = 16731606.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mucins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 15
  • [Other-IDs] NLM/ PMC1860402
  •  go-up   go-down


5. Fiorella R, Di Nicola V, Fiorella ML, Spinelli DA, Coppola F, Luperto P, Madami L: Major salivary gland diseases. Multicentre study. Acta Otorhinolaryngol Ital; 2005 Jun;25(3):182-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This multicentre study involved 28 Italian ORL Centres responding to a questionnaire sent by us which allowed recruitment of a high large number of cases of parotid neoplasms observed over a 10-year period.
  • Benign tumours account for 80% of case histories with a relationship 1:4 M/F, the most frequent being pleomorphic adenoma (57.3% of cases), followed by Warthin's tumour (32.4%), this rating not having been confirmed in case histories (8-10%) in the literature.
  • Adenoid-cystic carcinoma was observed in 15.3% and < or = 10% for all the other most frequent histological malignant neoplasms.
  • Surgical treatment of benign tumours consisted, in 50% of cases, in superficial paroditectomy and in approximately 30% of total paroditectomy.
  • Enucleoresection was limited to approximately 15% of neoplasms, enucleation to <10% of cases with only 2% of pleomorph adenoma due to the well-known anatomo-pathological characteristics which may lead to relapse.
  • For malignant neoplasms, total parotidectomy was performed in approximately 50% of cases, while in the remaining 50% an almost equal rate of superficial parotidectomy was carried out and enlarged parotidectomy, with or without sacrificing the facial nerve, which was rebuilt in 60% of cases.
  • When no clinically evident lymph nodes were present (NO) considering the tumour histotype, two thirds of patients underwent surgery or radiotherapy, while in the remainder the wait-and-see attitude was prefered.
  • Oncological results obtained were compared with those reported in the literature: in fact for all benign neoplasms relapse ratings are about 5%, while for malignant tumours the worst prognosis was in squamous cell carcinoma with median of 37.7 on survival and metastasis rate of 16.5%.
  • [MeSH-major] Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas Radiol. 1999 Nov;43(4):520-2 [10901971.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1984-8 [11801983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):729-38 [11849796.001]
  • [Cites] Atlas Oral Maxillofac Surg Clin North Am. 1998 Mar;6(1):1-28 [11905347.001]
  • [Cites] J Laryngol Otol. 2002 Apr;116(4):285-7 [11945190.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2002 Apr;22(2):80-5 [12068476.001]
  • [Cites] J Laryngol Otol. 2002 May;116(5):359-62 [12080993.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2141-54 [12461331.001]
  • [Cites] Mund Kiefer Gesichtschir. 2003 Mar;7(2):94-101 [12664254.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):931-40 [12820326.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):57-62 [12842751.001]
  • [Cites] Laryngoscope. 2003 Aug;113(8):1299-303 [12897549.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):257-9 [12903612.001]
  • [Cites] J Laryngol Otol. 2003 Aug;117(8):624-9 [12956917.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):929-33 [12975263.001]
  • [Cites] World J Surg. 2003 Jul;27(7):863-7 [14509520.001]
  • [Cites] Head Neck. 2003 Nov;25(11):946-52 [14603455.001]
  • [Cites] Chir Ital. 2003 Nov-Dec;55(6):857-64 [14725226.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6 [12883818.001]
  • [Cites] Otolaryngol Pol. 2004;58(1):109-14 [15101269.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):113-27 [15062365.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2005 Feb;23(1):53-6 [15804023.001]
  • [ErratumIn] Acta Otorhinolaryngol Ital. 2005 Oct;25(5):following 337
  • (PMID = 16450775.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2639866
  •  go-up   go-down


6. Ma TL, Ni PH, Zhong J, Tan JH, Qiao MM, Jiang SH: Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis; 2005;6(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low expression of XIAP-associated factor 1 in human colorectal cancers.
  • The aims of the present study were: (i) to investigate the expression of XAF1 in human colorectal cancers (CRC) both in vitro and in vivo, and (ii) to evaluate the possibility of XAF1 as a new tumor marker.
  • The expression of XAF1 in tissue was relatively lower in primary CRC compared with a relatively higher level in benign colorectal tumors (P < 0.01).
  • Although the XAF1 expression in circulation of those with CRC was also lower than in those with benign tumors, there was no statistical significance (P > 0.05).
  • CONCLUSIONS: The present results suggest that the low expression of XAF1 in tumor tissue coincides with a similar level in the peripheral circulation, which contributes at least part to the malignant behavior of CRC.
  • Integrating the XAF1 relative expression value with the other three traditional tumor biomarkers created a four-parameter assay that significantly improved the rate of diagnosis of CRC.
  • [MeSH-major] Biomarkers, Tumor / blood. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Aged. Apoptosis. Case-Control Studies. Female. Gene Expression Profiling. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Zinc Fingers

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667552.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / XAF1 protein, human
  •  go-up   go-down


7. Wang W, Feng B, Li X, Yin P, Gao P, Zhao X, Lu X, Zheng M, Xu G: Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry. Mol Biosyst; 2010 Oct;6(10):1947-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry.
  • Colorectal carcinoma (CRC) is the third most commonly encountered cancer and fourth cause of cancer-associated death worldwide.
  • In this study both ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) and online affinity solid phase extraction-high performance liquid chromatography (SPE-HPLC) were used to analyze the urinary metabolites from 34 healthy volunteers, 34 benign colorectal tumor and 50 colorectal carcinoma patients to produce comprehensive metabolic profiling data.
  • [MeSH-major] Chromatography, High Pressure Liquid / methods. Colorectal Neoplasms / urine. Mass Spectrometry / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20617254.001).
  • [ISSN] 1742-2051
  • [Journal-full-title] Molecular bioSystems
  • [ISO-abbreviation] Mol Biosyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


8. Bektas N, Noetzel E, Veeck J, Press MF, Kristiansen G, Naami A, Hartmann A, Dimmler A, Beckmann MW, Knüchel R, Fasching PA, Dahl E: The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res; 2008;10(4):R58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, alterations in the ISG15 signalling pathway have also been found in several human tumour entities.
  • ISG15 protein expression was analysed in two independent cohorts on tissue microarrays; in an initial evaluation set of 179 breast carcinomas and 51 normal breast tissues; and in a second large validation set of 646 breast carcinomas and 10 normal breast tissues.
  • In addition, a collection of benign and malignant mammary cell lines (n = 9) were investigated for ISG15 expression.
  • CONCLUSION: Therefore, ISG15 may represent a novel breast tumour marker with prognostic significance and may be helpful in selecting patients for and predicting response to the treatment of human breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Cytokines / metabolism. Cytokines / physiology. Gene Expression Regulation, Neoplastic. Ubiquitin / metabolism. Ubiquitins / metabolism. Ubiquitins / physiology
  • [MeSH-minor] Cell Line, Tumor. Cohort Studies. DNA, Complementary / metabolism. Disease-Free Survival. Humans. Immunohistochemistry / methods. Prognosis. RNA / metabolism. RNA, Messenger / metabolism. Recurrence. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2000;922:306-8 [11193908.001]
  • [Cites] Nature. 1997 Sep 18;389(6648):300-5 [9305847.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15623-8 [9861020.001]
  • [Cites] J Interferon Cytokine Res. 2004 Nov;24(11):647-54 [15684817.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10200-5 [16009940.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3271-8 [16101138.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Oct 21;336(2):496-506 [16139798.001]
  • [Cites] Nat Rev Immunol. 2005 Dec;5(12):941-52 [16322747.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):921-8 [16424026.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1453-9 [16187283.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1465-71 [16641915.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):235-9 [16682214.001]
  • [Cites] Oncogene. 2006 Jun 8;25(24):3479-88 [16449975.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3950-60 [16818692.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4790-3 [16914563.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Dec;17(6):411-21 [17097911.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4182-9 [17483329.001]
  • [Cites] Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):409-17 [17689132.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Aug;134(8):873-82 [18264724.001]
  • [Cites] Breast Cancer Res Treat. 2008 Nov;112(1):89-98 [18049890.001]
  • [Cites] Mol Cell. 2003 Jul;12(1):5-14 [12887888.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 1;307(3):431-4 [12893238.001]
  • [Cites] Mol Cancer Ther. 2004 Feb;3(2):111-21 [14985451.001]
  • [Cites] Br J Cancer. 1982 Jan;45(1):80-5 [6277358.001]
  • [Cites] J Biol Chem. 1987 Aug 15;262(23):11315-23 [2440890.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] Lancet. 1987 Sep 26;2(8561):701-3 [2888939.001]
  • [Cites] Cancer Res. 1991 Apr 1;51(7):1817-22 [2004366.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] J Biol Chem. 1992 Apr 15;267(11):7806-13 [1373138.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2415-23 [11859133.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):16608-13 [12582176.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):37-42 [9428781.001]
  • (PMID = 18627608.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA, Complementary; 0 / RNA, Messenger; 0 / Ubiquitin; 0 / Ubiquitins; 60267-61-0 / ISG15 protein, human; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC2575531
  •  go-up   go-down


9. Sarela AI: Entirely laparoscopic radical gastrectomy for adenocarcinoma: lymph node yield and resection margins. Surg Endosc; 2009 Jan;23(1):153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric resections for gastrointestinal stromal tumour (GIST) or benign disease were excluded.
  • Lymphadenectomy was adequate in 89% of laparoscopic gastrectomies. pT3 tumours were at risk of noncurative resection, as described in large Western series of open gastrectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Laparoscopy. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2009 Aug;23(8):1924-6 [19444509.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):189-95 [16432351.001]
  • [Cites] Br J Surg. 2006 Mar;93(3):300-8 [16363014.001]
  • [Cites] Am J Surg. 2007 Dec;194(6):839-44; discussion 844 [18005781.001]
  • [Cites] Gastric Cancer. 2007;10(3):176-80 [17922096.001]
  • [Cites] Gastric Cancer. 2005;8(2):75-7 [15864713.001]
  • [Cites] Surg Technol Int. 2004;13:59-63 [15744676.001]
  • [Cites] J Gastrointest Surg. 1999 Jan-Feb;3(1):24-33 [10457320.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2476-81 [16634089.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Ann Surg. 2003 Nov;238(5):680-5 [14578729.001]
  • [Cites] Surg Endosc. 2008 Apr;22(4):980-4 [17690934.001]
  • [Cites] Surg Endosc. 2008 Apr;22(4):1002-7 [17768658.001]
  • [Cites] Am J Surg. 2006 Dec;192(6):837-42 [17161104.001]
  • [Cites] Am J Surg. 2000 Apr;179(4):316-9 [10875993.001]
  • [Cites] Ann Surg Oncol. 2003 Aug;10(7):783-91 [12900370.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):968-71 [12658427.001]
  • [Cites] Gastric Cancer. 2007;10(3):181-6 [17922097.001]
  • [Cites] Surg Endosc. 2005 Jul;19(7):933-8 [15920691.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):68-72 [17197967.001]
  • [Cites] Gastric Cancer. 2006;9(2):51-66 [16767357.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):362-71 [10973386.001]
  • [Cites] J Am Coll Surg. 2008 Mar;206(3):516-23 [18308224.001]
  • [Cites] Gastric Cancer. 2006;9(3):167-76 [16952034.001]
  • [Cites] Am J Surg. 2006 Jan;191(1):134-8 [16399124.001]
  • [Cites] Arch Surg. 2007 Feb;142(2):143-9; discussion 149 [17309965.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):232-7 [15650632.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):21-7 [17031743.001]
  • [Cites] Gastric Cancer. 2006;9(4):303-7 [17235633.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):28-33 [16960676.001]
  • (PMID = 18633671.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M: Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch; 2007 Aug;451 Suppl 1:S51-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the former group, a continuum of lesions is recognised ranging from benign typical carcinoids to atypical carcinoids (having a low-grade behaviour, although often associated with regional and distant metastases), to the highly aggressive poorly differentiated carcinomas of the small and large cell types.
  • In the mixed tumour group, the NE component is extensively represented in association with any of the non-small cell carcinoma subtypes (so-called combined carcinomas), or the NE component is restricted to a cell population scattered among adenocarcinoma cells (or more rarely within squamous or large cell carcinomas).
  • The molecular profile of NE tumours has been widely investigated to identify features helpful for the diagnosis, prognosis and even therapy for this special lung tumour category.
  • [MeSH-major] Lung Neoplasms / diagnosis. Neuroendocrine Tumors / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1267-76 [9777989.001]
  • [Cites] Lab Invest. 1983 Nov;49(5):519-37 [6138458.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):945-53 [16861964.001]
  • [Cites] J Pathol. 1998 Oct;186(2):151-6 [9924430.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Brain Pathol. 2000 Jul;10(3):395-401 [10885658.001]
  • [Cites] Pathol Int. 2006 Aug;56(8):434-9 [16872437.001]
  • [Cites] J Thorac Oncol. 2015 Sep;10 (9):1240-1242 [26291007.001]
  • [Cites] Int J Surg Pathol. 2000 Oct;8(4):317-322 [11494008.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1614-20 [2553880.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):838-44 [2394833.001]
  • [Cites] Oncogene. 2007 Oct 18;26(48):6927-36 [17471231.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10680-5 [16322211.001]
  • [Cites] Thorax. 1995 May;50(5):551-4 [7541167.001]
  • [Cites] Lancet. 2004 Mar 6;363(9411):775-81 [15016488.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6908-14 [12362273.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1284-91 [8608504.001]
  • [Cites] J Biol Chem. 1980 Aug 10;255(15):7386-90 [7391086.001]
  • [Cites] Cancer Biol Ther. 2002 Jan-Feb;1(1):65-9 [12170765.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1148-55 [15343518.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):175-82 [11957142.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3971-9 [12124329.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5119-22 [10537285.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8423-32 [16166321.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1835-41 [17311257.001]
  • [Cites] Oncogene. 1998 Jul 30;17 (4):475-9 [9696041.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1154-64 [15712207.001]
  • [Cites] Histopathology. 2005 Feb;46(2):195-201 [15693892.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1196-209 [15492986.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Sep;64(3):413-21 [5054879.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1222-9 [15026805.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2104-9 [11391591.001]
  • [Cites] Lab Invest. 1988 Jul;59(1):5-24 [2839735.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):653-8 [7755151.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]
  • [Cites] Histopathology. 1990 Oct;17(4):353-8 [2124206.001]
  • [Cites] Expert Opin Investig Drugs. 2005 Mar;14(3):313-28 [15833062.001]
  • [Cites] Neuroendocrinology. 2007;85(1):54-60 [17310129.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2006 Dec;50(4):272-87 [17043625.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):222-9 [14657947.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):109-17 [15788643.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] J Biol Chem. 1962 Dec;237:3811-4 [13959775.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):4144-50 [6744325.001]
  • [Cites] Pediatr Pathol. 1993 Mar-Apr;13(2):165-80 [8464778.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):229-33 [11556750.001]
  • [Cites] Jpn J Clin Oncol. 2007 Jan;37(1):16-22 [17060405.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):70-6 [16382115.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):529-53 [1709558.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):787-97 [11787852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Cancer. 2003 May 15;97(10):2487-97 [12733148.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):600-7 [10091733.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):557-64 [16465412.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1259-67 [15154011.001]
  • [Cites] Lung Cancer. 2006 Nov;54(2):155-62 [16938365.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2832-9 [15837730.001]
  • [Cites] Diagn Mol Pathol. 2000 Mar;9(1):47-57 [10718213.001]
  • [Cites] J Histochem Cytochem. 2002 Aug;50(8):1013-21 [12133904.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):272-9 [9496831.001]
  • [Cites] Oncogene. 2001 Mar 29;20(14):1678-87 [11313916.001]
  • (PMID = 17684766.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 63
  •  go-up   go-down


11. Celis JE, Cabezón T, Moreira JM, Gromov P, Gromova I, Timmermans-Wielenga V, Iwase T, Akiyama F, Honma N, Rank F: Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort. Mol Oncol; 2009 Jun;3(3):220-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive apocrine carcinomas (IACs), as defined by morphological features, correspond to 0.3-4% of all invasive ductal carcinomas (IDC), and despite the fact that they are histologically distinct from other breast lesions there are currently no standard molecular criteria available for their diagnosis and no unequivocal information as to their prognosis.
  • Establishing these apocrine-specific markers as best practice for the routine pathology evaluation of breast cancer, however, will require their validation in large cohorts of patients.
  • Towards this goal we have composed a panel of antibodies against components of an apocrine protein signature that includes probes against the apocrine-specific markers 15-prostaglandin dehydrogenase (15-PGDH), and acyl-CoA synthetase medium-chain family member 1 (ACSM1), in addition to a set of categorizing markers that are consistently expressed (AR, CD24) or not expressed (ERα, PgR, Bcl-2, and GATA-3) by apocrine metaplasia in benign breast lesions and apocrine sweat glands.
  • Samples were originally classified on the basis of cellular morphology with all cases having more than 90% of the tumour cells exhibiting cytological features typical of apocrine cells.
  • [MeSH-major] Apocrine Glands / metabolism. Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1313-20 [18042688.001]
  • [Cites] Acta Oncol. 2006;45(6):643-61 [16938807.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Biotechnol Annu Rev. 2008;14:143-70 [18606362.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):197-204 [17234468.001]
  • [Cites] Pathol Biol (Paris). 2009 Jun;57(4):324-33 [19070972.001]
  • [Cites] J Pathol. 2006 Mar;208(4):495-506 [16429394.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18649-57 [11901151.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Breast. 2005 Feb;14(1):3-10 [15695074.001]
  • [Cites] Eur J Cancer. 2008 Dec;44(18):2799-805 [19008097.001]
  • [Cites] Tissue Eng Part C Methods. 2008 Sep;14(3):261-71 [18694322.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1006-12 [17105822.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):149-59 [18212769.001]
  • [Cites] Curr Opin Biotechnol. 1999 Feb;10(1):16-21 [10047502.001]
  • [Cites] Mol Oncol. 2008 Dec;2(4):368-79 [19383358.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):235-44 [17329194.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1854-63 [16002278.001]
  • [Cites] Breast J. 2008 Mar-Apr;14(2):164-8 [18248561.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R53 [18559090.001]
  • [Cites] Mol Oncol. 2008 Oct;2(3):213-22 [19383342.001]
  • [Cites] Pathol Res Pract. 2005;201(7):479-86 [16164042.001]
  • [Cites] Mol Cell Proteomics. 2008 Oct;7(10):1795-809 [18632593.001]
  • [Cites] Histopathology. 2007 Mar;50(4):425-33 [17448017.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2463-71 [6254632.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2002 Dec;67(6):461-5 [12468268.001]
  • [Cites] Med Oncol. 1997 Jun;14(2):83-9 [9330267.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):339-46 [16892043.001]
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):231-6 [12610508.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):830-5 [14871808.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] Nat Methods. 2007 Apr;4(4):359-65 [17396127.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):462-83 [16316978.001]
  • [Cites] Histopathology. 2005 Aug;47(2):195-201 [16045781.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):24-32 [19383364.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] J Pathol. 2008 Oct;216(2):141-50 [18720457.001]
  • [Cites] Cancer. 1968 Apr;21(4):756-63 [4296681.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2001;2:343-72 [11701654.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):832-5 [12766589.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Histopathology. 2008 Jan;52(1):108-18 [18171422.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Nov;4(11):1391-402 [18950281.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):532-41 [3717305.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):321-49 [19383306.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Histopathology. 2008 Jan;52(1):3-10 [18171412.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):838-41 [10690175.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] Pathobiology. 2008;75(2):119-31 [18544967.001]
  • [Cites] Mol Oncol. 2009 Jun;3(3):220-37 [19393583.001]
  • [Cites] Nat Cell Biol. 2007 Feb;9(2):201-9 [17187062.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):42-54 [19383286.001]
  • [Cites] J Gastrointest Cancer. 2007;38(2-4):78-82 [19031117.001]
  • [Cites] Breast J. 2003 Jul-Aug;9(4):335-6 [12846876.001]
  • [Cites] Pathology. 2009 Jan;41(1):68-76 [19089742.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Nature. 2005 Sep 22;437(7058):491-3 [16177777.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Feb;24(2):223-8 [3356211.001]
  • [Cites] Nat Clin Pract Urol. 2008 Jul;5(7):376-87 [18542103.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7917-25 [16140963.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):33-44 [19383365.001]
  • [Cites] Breast. 2005 Feb;14(1):1-2 [15695073.001]
  • [Cites] Breast Cancer Res. 2007;9(3):R30 [17504517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Int J Clin Pract. 2008 Mar;62(3):444-9 [18194278.001]
  • [Cites] Mol Oncol. 2007 Sep;1(2):144-59 [18443658.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1041-55 [17129787.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):580-92 [17668425.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • (PMID = 19393583.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


13. Ram H, Mohammad S, Husain N, Gupta PN: Ameloblastic carcinoma. J Maxillofac Oral Surg; 2010 Dec;9(4):415-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastic carcinoma (AC) is a rare aggressive malignant epithelial odontogenic tumor of the maxillofacial skeleton with a distinct predilection in the mandible.
  • It may present as a cystic lesion with benign clinical features or as a large tissue mass with ulceration, significant bone resorption and tooth mobility.
  • Direct extension of the tumour, lymph node involvement and metastasis to various sites has been reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22190836.001).
  • [ISSN] 0974-942X
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3177477
  • [Keywords] NOTNLM ; Ameloblastic carcinoma / Ameloblastoma / Odontogenic tumor
  •  go-up   go-down


14. Remzi M, Katzenbeisser D, Waldert M, Klingler HC, Susani M, Memarsadeghi M, Heinz-Peer G, Haitel A, Herwig R, Marberger M: Renal tumour size measured radiologically before surgery is an unreliable variable for predicting histopathological features: benign tumours are not necessarily small. BJU Int; 2007 May;99(5):1002-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal tumour size measured radiologically before surgery is an unreliable variable for predicting histopathological features: benign tumours are not necessarily small.
  • OBJECTIVE: To compare histopathological findings as a function of radiological tumour size, as published data suggest that small renal tumours are often benign and large tumours are renal cell cancer (RCC).
  • Tumour size measured by computed tomography (CT) before surgery was stratified into seven subgroups (cm): 0-2, 2.1-3, 3.1-4, 4.1-5, 5.1-6, 6.1-7 and >7, and correlated with final histology.
  • RESULTS: In all, 80 lesions (14.7%) were benign on final histology; tumour size did not correlate with benign histology (P=0.660).
  • Histopathological tumour size was not statistically significant different (P=0.521) from measured tumour size on CT, and there was no statistical significance between CT and histopathological tumour size (P=0.528).
  • Only 13 (17%) of lesions were correctly defined as benign on CT before surgery, whereas 67 (83%) were considered to be suspicious for malignant disease.
  • Only one patient with a tumour correctly defined as benign had a radical nephrectomy; by contrast, 28 of 67 (42%) had a radical nephrectomy for benign lesions not correctly identified as benign on CT before surgery (P<0.001).
  • CONCLUSION: Substantially many renal masses are benign, independent of tumour size.
  • Radical nephrectomy could potentially have been avoided in 42% of patients with benign renal tumours.
  • [MeSH-major] Kidney / pathology. Kidney Neoplasms / pathology. Tomography, X-Ray Computed / standards

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17437434.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution.
  • PURPOSE: Endoscopically unresectable apparently benign colorectal polyps are considered by some surgeons as ideal for their early laparoscopic colectomy experience.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • METHODS: Data from a consecutive series of patients undergoing laparoscopic colectomy (on an intention-to-treat basis) for endoscopically unresectable neoplasms with benign preoperative histology were retrieved from a prospective database and supplemented by chart review.
  • The median nodal harvest was 12 and all resection margins were free of neoplasm.
  • Mean diameter of benign tumors was 3.2 cm (range 0.5-10.0cm) versus 3.9cm (range 1.5-7.5cm) for adenocarcinomas (p = 0.189, t - test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • This finding supports the practice of performing oncological resection for all patients with endoscopically unresectable neoplasms of the colorectum.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Ann Surg. 1979 Dec;190(6):679-83 [518167.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Schache AG, Hall G, Woolgar JA, Nikolaidis G, Triantafyllou A, Lowe D, Risk JM, Shaw RJ, Liloglou T: Quantitative promoter methylation differentiates carcinoma ex pleomorphic adenoma from pleomorphic salivary adenoma. Br J Cancer; 2010 Dec 7;103(12):1846-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: potential epigenetic biomarkers for malignant transformation to carcinoma ex pleomorphic adenoma (Ca ex PSA) have been sought previously with and without specific comparison with the benign variant, pleomorphic salivary adenoma (PSA).
  • We sought to demonstrate quantitative promoter methylation across a panel of tumour suppressor genes (TSGs) in both Ca ex PSA and PSA.
  • METHODS: quantitative methylation-specific real-time polymerase chain reaction (qMSP) analysis of p16(INK4A), CYGB, RASSF1, RARβ, human telomerase reverse transcriptase (hTERT), Wilms' tumour 1 (WT1) and TMEFF2 gene promoters was undertaken on bisulphite-converted DNA, previously extracted from archival fixed tissue specimens of 31 Ca ex PSA and an unrelated cohort of 28 PSA.
  • CONCLUSIONS: we demonstrate the successful application of qMSP to a large series of historical Ca ex PSA samples and report on a panel of TSGs with significant differences in their methylation profiles between benign and malignant variants of pleomorphic salivary adenoma. qMSP analysis could be developed as a useful clinical tool to differentiate between Ca ex PSA and its benign precursor.
  • [MeSH-major] Adenoma, Pleomorphic / genetics. DNA Methylation. Promoter Regions, Genetic. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Genes, Tumor Suppressor. Humans. Membrane Proteins / genetics. Neoplasm Proteins / genetics. Polymerase Chain Reaction. Telomerase / genetics. WT1 Proteins / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Cancer Resaerch UK.
  • [Cites] J Oral Pathol Med. 2008 May;37(5):309-18 [18248354.001]
  • [Cites] Acta Otolaryngol. 2007 Nov;127(11):1207-13 [17851915.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2664-72 [18451230.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2174-9 [18708411.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2594-604 [18792900.001]
  • [Cites] Carcinogenesis. 2009 Jan;30(1):28-34 [18952593.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):1051-9 [19194757.001]
  • [Cites] Oncol Rep. 2009 Jul;22(1):199-204 [19513524.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):4174-80 [19509163.001]
  • [Cites] Int J Cancer. 2010 Apr 1;126(7):1630-9 [19795445.001]
  • [Cites] Diagn Cytopathol. 1999 Sep;21(3):163-6 [10450099.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1924-30 [16134181.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):561-8 [16449996.001]
  • [Cites] J Cell Physiol. 2006 Jun;207(3):654-9 [16447252.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7353-8 [17189407.001]
  • [Cites] Int J Oncol. 2007 Jun;30(6):1349-57 [17487355.001]
  • [Cites] Oral Oncol. 2007 Oct;43(9):878-86 [17257884.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72 [17878233.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] Head Neck. 2001 Sep;23(9):705-12 [11505478.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1747-52 [11717336.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4309-18 [12024041.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Cancer Sci. 2003 Jun;94(6):523-9 [12824878.001]
  • [Cites] Mol Pathol. 2003 Aug;56(4):226-31 [12890744.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):407-16 [15099954.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):180-90 [15269293.001]
  • [Cites] Acta Otolaryngol. 1974 Jun;77(6):426-32 [4365171.001]
  • [Cites] Biotechniques. 1995 May;18(5):768-70, 772-3 [7619474.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):551-7 [9973199.001]
  • [Cites] Jpn J Cancer Res. 1999 Feb;90(2):194-204 [10189890.001]
  • [Cites] Histopathology. 2007 Nov;51(5):691-6 [17927591.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):161-7 [18398837.001]
  • (PMID = 21063414.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / TMEFF2 protein, human; 0 / WT1 Proteins; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC3008600
  •  go-up   go-down


17. Bensalah K, Pantuck AJ, Crepel M, Verhoest G, Méjean A, Valéri A, Ficarra V, Pfister C, Ferrière JM, Soulié M, Cindolo L, De La Taille A, Tostain J, Chautard D, Schips L, Zigeuner R, Abbou CC, Lobel B, Salomon L, Lechevallier E, Descotes JL, Guillé F, Colombel M, Belldegrun AS, Patard JJ: Prognostic variables to predict cancer-related death in incidental renal tumours. BJU Int; 2008 Nov;102(10):1376-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To identify, in a large multicentre series of incidental renal tumours, the key factors that could predict cancer-related deaths, as such tumours have a better outcome than symptomatic tumours and selected patients are increasingly being included in watchful-waiting protocols.
  • Age, gender, Eastern Cooperative Oncology Group (ECOG) performance status (PS), Tumour-Node-Metastasis (TNM) stage, tumour size, Fuhrman grade, and final pathology were recorded.
  • Benign tumours and malignant lesions with incomplete information were excluded from final analysis.
  • RESULTS: The mean (SD) age of the patients was 60.6 (12.2) years and the mean tumour size 5.5 (3.5) cm.
  • Multivariable analysis showed that tumour size >4 cm, ECOG PS >or=1, TNM stage and Fuhrman grade were independent predictors of cancer-related death.
  • A watchful-waiting strategy should not be recommended if the tumour diameter is >4 cm, if biopsy confirms high-grade tumours, or if there is an impaired ECOG PS, or computed tomography findings suggest the presence of advanced T stage.
  • [MeSH-major] Carcinoma, Renal Cell / mortality. Incidental Findings. Kidney Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Nephrectomy / methods. Prognosis. Retrospective Studies. Survival Analysis. Young Adult


18. Lanitis S, Sivakumar S, Behranwala K, Zacharakis E, Al Mufti R, Hadjiminas DJ: A case of Meigs syndrome mimicking metastatic breast carcinoma. World J Surg Oncol; 2009;7:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nevertheless, benign ovarian masses can mimic this clinical picture when they are associated with Meigs' syndrome making the work-up and management of these patients challenging.
  • Pre-treatment staging investigations showed a 13.5 cm mass in her left ovary, a small amount of ascites and a large right pleural effusion.
  • Serum tumour markers showed a raised CA125 supporting the malignant nature of the ovarian mass.
  • After a good response to the hormone manipulation, the patient had breast conserving surgery, axillary sampling and laparoscopic excision of the ovarian mass which was eventually found to be a benign ovarian fibroma.
  • CONCLUSION: Despite the high probability of disseminated malignancy when an ovarian mass associated with ascites if found in a patient with a breast cancer and pleural effusion, clinicians should be aware about rare benign syndromes, like Meigs', which may mimic a similar picture and mislead the diagnosis and management plan.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroma / diagnosis. Meigs Syndrome / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. CA-125 Antigen / blood. Diagnosis, Differential. Female. Gynecologic Surgical Procedures. Humans. Mastectomy. Middle Aged. Nitriles / therapeutic use. Pleural Effusion / diagnosis. Pleural Effusion / drug therapy. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. LETROZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Jul;216(1):242-7 [10887255.001]
  • [Cites] Breast Cancer. 2006;13(4):344-8 [17146160.001]
  • [Cites] Am J Clin Oncol. 1989 Oct;12(5):369-74 [2801596.001]
  • [Cites] J Comput Assist Tomogr. 1990 Sep-Oct;14(5):833-4 [2398172.001]
  • [Cites] Gynecol Obstet Invest. 1992;33(1):54-8 [1563658.001]
  • [Cites] J Surg Oncol. 1994 Jun;56(2):71-4 [8007681.001]
  • [Cites] Obstet Gynecol. 1994 Sep;84(3):449-52 [8058246.001]
  • [Cites] Radiographics. 1994 Jul;14(4):747-60; discussion 761-2 [7938766.001]
  • [Cites] J Anat. 1995 Jun;186 ( Pt 3):453-67 [7559120.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Jan;82(1):97-9 [10192495.001]
  • [Cites] Am J Obstet Gynecol. 1954 May;67(5):962-85 [13148256.001]
  • [Cites] J Int Coll Surg. 1964 Dec;42:625-30 [14209105.001]
  • [Cites] Obstet Gynecol. 2005 Mar;105(3):507-13 [15738016.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:315-8 [16515612.001]
  • [Cites] J Thorac Imaging. 2003 Apr;18(2):100-3 [12700485.001]
  • (PMID = 19161612.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  • [Other-IDs] NLM/ PMC2633000
  •  go-up   go-down


19. Perez DE, Lopes MA, de Almeida OP, Jorge J, Kowalski LP: Plasmacytoid myoepithelioma of the palate in a child. Int J Paediatr Dent; 2007 May;17(3):223-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Myoepithelioma is a rare benign salivary gland tumour, localized most frequently in the parotid and in minor intraoral salivary glands.
  • Incisional biopsy was performed and revealed large plasmacytoid cells with a round and eccentric nuclei.
  • The diagnosis was consistent with myoepithelioma, plasmocytoid variant.
  • Tumour cells were positive for cytokeratins, vimentin and S-100 protein.
  • Surgical resection was performed and no evidences of tumour recurrence were observed after 6 years of the treatment.
  • CONCLUSION: Myoepithelioma is a very rare tumour in children and apparently presents a good prognosis, similar to occur in adult patients.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17397468.001).
  • [ISSN] 0960-7439
  • [Journal-full-title] International journal of paediatric dentistry
  • [ISO-abbreviation] Int J Paediatr Dent
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


20. Chan PT, Tripathi S, Low SE, Robinson LQ: Case report--ancient schwannoma of the scrotum. BMC Urol; 2007;7:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Scrotal schwannoma is a rare neoplasm and poses a diagnostic challenge to urologists.
  • This article describes a rare case of ancient scrotal schwannoma and reviews the current modality of investigation and treatment of this tumour.
  • CONCLUSION: Schwannoma is a benign encapsulating neoplasm with an overall low incidence, occurring mostly in the head and neck region and seldom in the scrotum.
  • Ancient schwannoma exhibits pleomorphism without mitosis as the result of cellular degeneration, which can lead to an erroneous diagnosis of malignancy.
  • Imaging modalities are non-specific for schwannomas, but can define tumour size, site and extension.
  • The mainstay treatment is complete excision, although local recurrence may occur in large and incompletely excised lesions.
  • [MeSH-major] Genital Neoplasms, Male / diagnosis. Genital Neoplasms, Male / therapy. Neurilemmoma / diagnosis. Neurilemmoma / therapy

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Craniomaxillofac Surg. 2006 Jan;34(1):38-42 [16343919.001]
  • [Cites] Hinyokika Kiyo. 2002 Dec;48(12):749-51 [12613010.001]
  • [Cites] J Korean Med Sci. 2003 Apr;18(2):295-8 [12692434.001]
  • [Cites] Urology. 2003 Dec;62(6):993-7 [14665342.001]
  • [Cites] Pancreatology. 2004;4(6):505-8 [15316226.001]
  • [Cites] J R Soc Med. 1992 Jul;85(7):416-7 [1629853.001]
  • [Cites] Actas Urol Esp. 1997 Nov-Dec;21(10):1012-3 [9494170.001]
  • [Cites] Urol Int. 1998;60(3):202-4 [9644798.001]
  • [Cites] AJR Am J Roentgenol. 2004 Aug;183(2):331-6 [15269020.001]
  • (PMID = 17244372.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  • [Other-IDs] NLM/ PMC1783662
  •  go-up   go-down


21. Zafrakas M, Chorovicer M, Klaman I, Kristiansen G, Wild PJ, Heindrichs U, Knüchel R, Dahl E: Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue. Int J Cancer; 2006 Mar 15;118(6):1453-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GABRP downregulation in breast cancer was confirmed by quantitative RT-PCR in cryopreserved breast tumour and normal breast tissue specimens (n = 22), in archival formalin-fixed, paraffin-embedded tissue specimens (n = 32), as well as in breast cancer cell lines (n = 8).
  • Furthermore, a significant downregulation of GABRP was noted in large (pT3-pT4) (p = 0.044) primary breast tumours.
  • Non-radioisotopic ISH showed strong GABRP expression in normal epithelial and benign papilloma breast cells, but no signal could be detected in invasive ductal carcinoma.
  • Altogether, these data suggest that GABRP is progressively down-regulated with tumour-progression, and that it may be useful as a prognostic marker in breast cancer.
  • [MeSH-major] Breast / metabolism. Breast Neoplasms / genetics. Protein Subunits / genetics. Receptors, GABA-A / genetics
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization / methods. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction


22. Health Quality Ontario: Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis. Ont Health Technol Assess Ser; 2006;6(17):1-121
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.
  • OBJECTIVE: The Ontario Health Technology Advisory Committee asked the Medical Advisory Secretariat (MAS) to conduct a health technology assessment on energy delivery systems for the treatment of benign prostatic hyperplasia (BPH).
  • CLINICAL NEED: TARGET POPULATION AND CONDITION BPH is a noncancerous enlargement of the prostate gland and the most common benign tumour in aging men. (1) It is the most common cause of lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) and is an important cause of diminished quality of life among aging men. (2) The primary goal in the management of BPH for most patients is a subjective improvement in urinary symptoms and quality of life.
  • However, the results were not significant at longer-term follow-up periods.Two RCTs that provided 3-year follow-up data reported that patients undergoing TUMT had a significantly lesser improvement in symptom score compared with patients undergoing TURP.RCTs reported a longer duration of catheterization for TUMT compared with TURP (P values are not reported).The results of a large RCT with 5-year follow-up showed a significantly lesser improvement in symptom scores in patients undergoing TUNA compared with patients undergoing TURP.Meta-analysis of the rate of reoperation showed that patients undergoing TUNA had a significantly higher rate of reoperation compared with patients undergoing TURP.Based on the results of RCTs, TURP is associated with a 0.5% risk of TUR syndrome, while no cases of TUR syndrome have been reported in patients undergoing monopolar or bipolar electrovaporization, laser-based procedures, TUMT, or TUNA.Based on the results of RCTs, the rate of blood transfusion ranges from 0% to 8.3% in patients undergoing TURP.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1996 May;47(5):672-7; discussion 677-8 [8650864.001]
  • [Cites] J Urol. 1996 Nov;156(5):1662-7 [8863566.001]
  • [Cites] Urology. 1998 Jan;51(1):19-28 [9457283.001]
  • [Cites] Urology. 1998 Mar;51(3):422-7 [9510347.001]
  • [Cites] Urology. 1998 Apr;51(4A Suppl):1-7 [9586589.001]
  • [Cites] Mayo Clin Proc. 1998 Aug;73(8):798-801 [9703311.001]
  • [Cites] BJU Int. 2000 Jan;85(1):74-8 [10619950.001]
  • [Cites] Urology. 2000 Feb;55(2):231-5 [10688085.001]
  • [Cites] J Urol. 2000 Jun;163(6):1730-3 [10799170.001]
  • [Cites] Urology. 2000 Jun;55(6):886-90; discussion 890-1 [10840101.001]
  • [Cites] J Urol. 2000 Jul;164(1):59-64 [10840425.001]
  • [Cites] J Urol. 2000 Jul;164(1):65-70 [10840426.001]
  • [Cites] BJU Int. 2000 Oct;86(6):648-51 [11069371.001]
  • [Cites] Urology. 2004 Oct;64(4):698-702 [15491704.001]
  • [Cites] Asian J Surg. 2005 Jan;28(1):24-8 [15691793.001]
  • [Cites] BJU Int. 2005 Mar;95(4):557-62 [15705080.001]
  • [Cites] J Endourol. 2005 Jan-Feb;19(1):79-82 [15735389.001]
  • [Cites] J Ayub Med Coll Abbottabad. 2004 Oct-Dec;16(4):16-20 [15762056.001]
  • [Cites] J Endourol. 2005 Jul-Aug;19(6):734-7 [16053367.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):965-71; discussion 972 [16126327.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1339-43 [16145415.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1344-8 [16145416.001]
  • [Cites] Eur J Cancer Prev. 2002 Oct;11(5):473-9 [12394245.001]
  • [Cites] J Endourol. 2002 Dec;16(10):767-71 [12542882.001]
  • [Cites] BJU Int. 2003 Feb;91(3):211-4 [12581006.001]
  • [Cites] Urology. 2003 Mar;61(3):573-8 [12639650.001]
  • [Cites] J Endourol. 2003 Mar;17(2):103-7 [12689404.001]
  • [Cites] Urology. 2003 Jun;61(6):1166-71 [12809891.001]
  • [Cites] Urol Int. 2003;71(1):26-30 [12845256.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1270-4 [14501739.001]
  • [Cites] Urology. 2003 Dec;62(6):1029-34 [14665349.001]
  • [Cites] Scand J Urol Nephrol. 2003;37(6):487-93 [14675922.001]
  • [Cites] Scand J Urol Nephrol. 2003;37(6):494-7 [14675923.001]
  • [Cites] J Endourol. 2004 Mar;18(2):189-91 [15072629.001]
  • [Cites] Curr Opin Urol. 2004 Jan;14(1):31-4 [15091047.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2336-40 [15126816.001]
  • [Cites] Can J Urol. 2004 Apr;11(2):2186-93 [15182407.001]
  • [Cites] J Urol. 2004 Aug;172(2):616-9 [15247745.001]
  • [Cites] J Urol. 2004 Sep;172(3):1012-6 [15311026.001]
  • [Cites] Urology. 1997 Aug;50(2):167-72 [9255283.001]
  • [Cites] Eur Urol. 2000 Sep;38(3):265-71 [10940699.001]
  • [Cites] Eur Urol. 2000 Nov;38(5):569-75 [11096238.001]
  • [Cites] Eur Urol. 2000;38 Suppl 1:7-17 [11111204.001]
  • [Cites] J Urol. 2001 May;165(5):1533-8 [11342912.001]
  • [Cites] Eur Urol. 2001 Sep;40(3):256-63; discussion 264 [11684840.001]
  • [Cites] BJU Int. 2002 Dec;90(9):853-62 [12460345.001]
  • [Cites] J Urol. 2003 Apr;169(4):1411-6 [12629374.001]
  • [Cites] BMJ. 2004 Jun 19;328(7454):1490 [15205295.001]
  • [Cites] BJU Int. 2004 Aug;94(3):327-31 [15291861.001]
  • [Cites] Curr Opin Urol. 2005 Jan;15(1):55-8 [15586032.001]
  • [Cites] Health Technol Assess. 2005 Feb;9(4):iii-iv, 1-30 [15698525.001]
  • [Cites] Can J Urol. 2005 Jun;12(3):2677-83 [16011814.001]
  • [Cites] BJU Int. 2005 Aug;96(3):368-72 [16042732.001]
  • [Cites] Am J Med. 2005 Dec;118(12):1331-9 [16378773.001]
  • [Cites] Urology. 2006 Jan;67(1):69-72 [16413335.001]
  • [Cites] Int J Urol. 2006 Jan;13(1):21-4 [16448427.001]
  • [Cites] BMJ. 2006 Apr 8;332(7545):853-4 [16601055.001]
  • [Cites] Hinyokika Kiyo. 2006 Aug;52(8):609-14 [16972622.001]
  • [Cites] Urology. 1994 Aug;44(2):156-8 [7519379.001]
  • [Cites] Br J Urol. 1994 Nov;74(5):542-50 [7530115.001]
  • [Cites] J Urol. 2005 Nov;174(5):1896-901; discussion 1901 [16217332.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2006;9(1):30-4 [16231014.001]
  • [Cites] BJU Int. 2006 Jan;97(1):85-9 [16336334.001]
  • [Cites] Clin Genitourin Cancer. 2005 Dec;4(3):187-92 [16425987.001]
  • [Cites] Urol Int. 2006;76(2):139-43 [16493215.001]
  • [Cites] Urol Int. 2006;76(2):144-9 [16493216.001]
  • [Cites] Urology. 2006 Jun;67(6):1193-8 [16750253.001]
  • [Cites] J Urol. 2006 Jul;176(1):205-9 [16753403.001]
  • [Cites] J Urol. 1992 Nov;148(5):1549-57; discussion 1564 [1279218.001]
  • [Cites] J Urol. 1973 Aug;110(2):229-31 [4124677.001]
  • [Cites] J Urol. 1984 Sep;132(3):474-9 [6206240.001]
  • [Cites] Urology. 1994 Aug;44(2):153-5 [7519378.001]
  • [Cites] J Urol. 1994 Dec;152(6 Pt 1):1956-60; discussion 1960-1 [7525992.001]
  • [Cites] BJU Int. 2000 Nov;86(7):805-15 [11069405.001]
  • [Cites] J Endourol. 2000 Nov;14(9):757-60 [11110572.001]
  • [Cites] J Endourol. 2001 Apr;15(3):317-21 [11339401.001]
  • [Cites] J Urol. 2001 Jul;166(1):166-70; discussion 170-1 [11435848.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 2):999-1003; discussion 1004 [11908420.001]
  • [Cites] Urology. 2002 Aug;60(2):292-9 [12137829.001]
  • [Cites] Urology. 2002 Aug;60(2):305-8 [12137831.001]
  • [Cites] J Urol. 2002 Sep;168(3):1058-62 [12187222.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1465-9 [12352419.001]
  • [Cites] Lasers Surg Med. 1995;16(4):312-30 [7651053.001]
  • [Cites] Semin Surg Oncol. 1995 Jan-Feb;11(1):9-22 [7754280.001]
  • [Cites] Cancer Invest. 1994;12(4):425-37 [8032966.001]
  • [Cites] Urology. 1996 Jan;47(1):48-51 [8560662.001]
  • (PMID = 23074487.001).
  • [ISSN] 1915-7398
  • [Journal-full-title] Ontario health technology assessment series
  • [ISO-abbreviation] Ont Health Technol Assess Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3379165
  •  go-up   go-down


23. Shirodkar SP, Lokeshwar VB: Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? Expert Rev Anticancer Ther; 2008 Jul;8(7):1111-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?
  • Currently, the detection of initial tumors and recurrent disease is based on evaluation of voided urinary specimens, often followed by cystoscopy.
  • As a result, intense work is being done in the field of bladder tumor markers with the goal of identifying bladder cancer earlier, both in the initial diagnosis and in recurrences of known tumor.
  • The possibility of identifying a marker that could noninvasively differentiate benign and malignant causes of hematuria, and identify recurrences prior to their pathologic progression is the objective of this area of research.
  • Currently, a large number of tumor markers exist, each scrutinized in both the laboratory and in clinical trials.
  • Some novel modalities for tumor detection are also presented.
  • Studies continue to refine the role of these markers in clinical practice, but their ultimate efficacy will need to be borne out in large-scale clinical trials in a multitude of settings.
  • [MeSH-major] Biomarkers, Tumor / genetics. Biomarkers, Tumor / urine. Hematuria / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / urine. Cystoscopy. Humans. Molecular Diagnostic Techniques / methods. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2007;13(3):187-94 [17922047.001]
  • [Cites] J Urol. 2007 Jan;177(1):80-3 [17162008.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):53-61 [10696245.001]
  • [Cites] Int J Oncol. 1993 Oct;3(4):559-63 [21573400.001]
  • [Cites] Urology. 2005 Dec;66(6 Suppl 1):35-63 [16399415.001]
  • [Cites] Urology. 2000 Nov 1;56(5):793-7 [11068304.001]
  • [Cites] Lancet. 1993 Aug 21;342(8869):469-71 [8102431.001]
  • [Cites] Eur Urol. 1999 Jan;35(1):52-6 [9933795.001]
  • [Cites] World J Urol. 2008 Feb;26(1):59-65 [17962949.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1701-7 [16541433.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):61-72 [12115318.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):369-73 [14663639.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 21;87(12):884-94 [7666477.001]
  • [Cites] Cancer Pract. 2002 Nov-Dec;10(6):311-22 [12406054.001]
  • [Cites] Int Surg. 1991 Jan-Mar;76(1):52-4 [2045253.001]
  • [Cites] JAMA. 2005 Feb 16;293(7):810-6 [15713770.001]
  • [Cites] J Urol. 2007 Apr;177(4):1277-82; discussion 1282 [17382711.001]
  • [Cites] Urol Oncol. 2006 Nov-Dec;24(6):528-37 [17138134.001]
  • [Cites] Hum Pathol. 2004 Jul;35(7):817-24 [15257544.001]
  • [Cites] J Urol. 2003 Jan;169(1):86-9 [12478110.001]
  • [Cites] J Urol. 2007 Feb;177(2):437-43 [17222605.001]
  • [Cites] Urology. 2001 Apr;57(4):680-4 [11306380.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):699-703 [8976763.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2173-9 [17029275.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):293-7 [12209982.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2511-20 [9796985.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):621-30 [14745881.001]
  • [Cites] J Urol. 2001 Aug;166(2):470-5 [11458049.001]
  • [Cites] JAMA. 2006 Jan 18;295(3):299-305 [16418465.001]
  • [Cites] Urology. 2000 Aug 1;56(2):228-31 [10925083.001]
  • [Cites] Urology. 2003 Jan;61(1):243-7 [12559316.001]
  • [Cites] World J Urol. 2004 Jun;22(2):145-9 [14991320.001]
  • [Cites] J Urol. 1998 Feb;159(2):394-8 [9649246.001]
  • [Cites] Chin Med J (Engl). 2006 Nov 5;119(21):1763-71 [17097029.001]
  • [Cites] J Urol. 2006 Sep;176(3):919-26; discussion 926 [16890655.001]
  • [Cites] World J Urol. 2006 Sep;24(4):418-22 [16688457.001]
  • [Cites] J Urol. 2002 Nov;168(5):1950-4 [12394683.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):634-9 [10953114.001]
  • [Cites] J Urol. 2001 Oct;166(4):1280-5 [11547058.001]
  • [Cites] J Urol. 1999 Jul;162(1):53-7 [10379739.001]
  • [Cites] Oncol Rep. 2007 Aug;18(2):405-9 [17611663.001]
  • [Cites] J Urol. 2006 Jun;175(6):2032-7; discussion 2037 [16697794.001]
  • [Cites] J Urol. 2002 Jan;167(1):80-3 [11743280.001]
  • [Cites] World J Urol. 2008 Feb;26(1):45-50 [18180926.001]
  • [Cites] Urology. 2006 Mar;67(3 Suppl 1):25-33; discussion 33-4 [16530072.001]
  • [Cites] Curr Opin Genet Dev. 1991 Dec;1(4):538-43 [1822287.001]
  • [Cites] Semin Diagn Pathol. 1997 May;14(2):123-32 [9179973.001]
  • [Cites] Can J Urol. 1997 Sep;4(3):400-405 [12735818.001]
  • [Cites] Urology. 1998 Nov;52(5):793-6 [9801101.001]
  • [Cites] Med Sci Monit. 2003 Apr;9(4):PI25-9 [12709681.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5352-8 [18048815.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4464-70 [10485499.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Jun;134(6):659-65 [18026991.001]
  • [Cites] Urology. 2004 Feb;63(2):392-7 [14972509.001]
  • [Cites] Urology. 2005 Dec;66(6):1256-60 [16360453.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1356-62 [15717321.001]
  • [Cites] BJU Int. 2006 Nov;98(5):1090-3 [17034609.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1280-5 [16287445.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):171-9 [11801555.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):100-4 [15761870.001]
  • [Cites] J Urol. 2000 Jan;163(1):348-56 [10604388.001]
  • [Cites] J Urol. 1996 Oct;156(4):1280-5 [8808854.001]
  • [Cites] Front Biosci. 2002 Jan 01;7:e27-32 [11779714.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):67-72 [11668480.001]
  • [Cites] ScientificWorldJournal. 2006 Mar 27;6:2617-25 [17619739.001]
  • [Cites] Semin Cancer Biol. 1996 Feb;7(1):15-24 [8695762.001]
  • [Cites] J Urol. 1997 Aug;158(2):338-41 [9224298.001]
  • [Cites] Ann Clin Lab Sci. 2006 Winter;36(1):31-8 [16501234.001]
  • [Cites] Am Fam Physician. 2001 Mar 15;63(6):1145-54 [11277551.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):588-97 [12697851.001]
  • [Cites] Asian J Androl. 2007 Sep;9(5):711-5 [17712491.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):845-52 [12808119.001]
  • [Cites] BJU Int. 2008 Jan;101(1):26-9 [17850364.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):83-9 [15389253.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2):75-84 [17382791.001]
  • [Cites] BJU Int. 2007 Feb;99(2):281-5 [17155984.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Mar;173(2):131-5 [17321328.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • [Cites] Urology. 2003 Nov;62(5):952-7 [14624933.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):274-80 [15900578.001]
  • [Cites] Urol Int. 2001;66(4):185-90 [11385303.001]
  • [Cites] J Natl Cancer Inst. 1997 May 21;89(10):724-30 [9168188.001]
  • [Cites] Eur Urol. 1990;17(4):281-5 [2364965.001]
  • [Cites] Nat Med. 1997 Jun;3(6):621-4 [9176487.001]
  • [Cites] Urol Oncol. 2001 Jul;6(4):163-169 [11418323.001]
  • [Cites] JAMA. 2001 Jan 17;285(3):324-8 [11176843.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1106-13 [17311310.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):295-301 [17210520.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 1):1971-4 [9817302.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 3):3-14 [11894002.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 1):1068-72 [17644139.001]
  • [Cites] Urology. 2001 Sep;58(3):367-71 [11549482.001]
  • [Cites] World J Urol. 2007 Dec;25(6):563-71 [17710407.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):49-60 [17275177.001]
  • [Cites] World J Urol. 2000 Dec;18(6):401-5 [11204258.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2618-25 [10914702.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1384-91 [14977841.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2914-22 [12115379.001]
  • [Cites] Urology. 2007 Sep;70(3):482-6 [17905101.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Urology. 2007 Sep;70(3):449-53 [17688921.001]
  • [Cites] Oncol Rep. 2006 May;15(5):1321-6 [16596205.001]
  • [Cites] Urol Clin North Am. 1998 Nov;25(4):661-76 [10026773.001]
  • [Cites] World J Urol. 2008 Feb;26(1):31-7 [18075743.001]
  • [Cites] Blood. 1995 May 1;85(9):2315-20 [7727765.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):329-38 [17373664.001]
  • [Cites] Pharmacoeconomics. 2003;21(18):1315-30 [14750899.001]
  • [Cites] Urology. 2000 Feb;55(2):223-6 [10688083.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):25-37 [10696242.001]
  • [Cites] J Urol. 1999 May;161(5):1486-9 [10210378.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):951-6; discussion 956 [16257108.001]
  • [Cites] JAMA. 2005 Oct 26;294(16):2052-6 [16249419.001]
  • [Cites] Indian J Med Sci. 2005 Jun;59(6):235-42 [15988093.001]
  • [Cites] Curr Opin Urol. 2007 Sep;17(5):352-7 [17762630.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1388-96 [17466450.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5519-27 [17158537.001]
  • [Cites] Curr Opin Urol. 2008 Jan;18(1):1-8 [18090481.001]
  • [Cites] J Urol. 2007 Jul;178(1):57-61 [17574060.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):678-86 [16129368.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2333-40 [10873084.001]
  • [Cites] Isr Med Assoc J. 2002 Mar;4(3):174-5 [11908255.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1423-7 [3304614.001]
  • [Cites] Med Clin North Am. 2004 Mar;88(2):329-43 [15049581.001]
  • [Cites] Int J Urol. 2007 Feb;14(2):108-11 [17302565.001]
  • [Cites] Br J Urol. 1991 Sep;68(3):248-53 [1717095.001]
  • [Cites] J Urol. 2004 Sep;172(3):1123-6 [15311054.001]
  • [Cites] Med Sci Monit. 2003 Aug;9 Suppl 3:25-8 [15156607.001]
  • [Cites] Urology. 2004 Dec;64(6):1121-6 [15596183.001]
  • [Cites] J Urol. 1999 Feb;161(2):443-6 [9915422.001]
  • [Cites] J Urol. 2007 Feb;177(2):481-7; discussion 487 [17222615.001]
  • [Cites] Urology. 1989 Feb;33(2):89-96 [2916296.001]
  • [Cites] Tumour Biol. 2007;28(2):57-62 [17259754.001]
  • [Cites] Eur Urol. 2004 Oct;46(4):466-71 [15363562.001]
  • (PMID = 18588456.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA072821; United States / NCI NIH HHS / CA / 5R01 CA-72821-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Number-of-references] 136
  •  go-up   go-down


24. Guttery DS, Hancox RA, Mulligan KT, Hughes S, Lambe SM, Pringle JH, Walker RA, Jones JL, Shaw JA: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res; 2010;12(4):R57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Tenascin-C (TNC) is a large extracellular matrix glycoprotein that shows prominent stromal expression in many solid tumours.
  • The profile of isoforms expressed differs between cancers and normal breast, with the two additional domains AD1 and AD2 considered to be tumour associated.
  • The aim of the present study was to investigate expression of AD1 and AD2 in normal, benign and malignant breast tissue to determine their relationship with tumour characteristics and to perform in vitro functional assays to investigate the role of AD1 in tumour cell invasion and growth.
  • Statistical analysis was performed using a nonparametric Mann-Whitney test for comparison of clinicopathological features with levels of TNC expression and using Jonckheere-Terpstra trend analysis for association of expression with tumour grade.
  • AD1 mRNA was localised by in situ hybridisation to tumour epithelial cells, and more predominantly to myoepithelium around associated normal breast ducts.
  • Although not tumour specific, AD1 and AD2 expression was significantly more frequent in carcinomas in younger women (age ≤40 years; P < 0.001) and AD1 expression was also associated with oestrogen receptor-negative and grade 3 tumours (P < 0.05).
  • AD1 was found to be incorporated into a tumour-specific isoform, not detected in normal tissues.
  • Overexpression of the TNC-14/AD1/16 isoform significantly enhanced tumour cell invasion (P < 0.01) and growth (P < 0.01) over base levels.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Jan;105(1):21-34 [10619858.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1796-800 [8956795.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):581-96 [11102748.001]
  • [Cites] Lancet. 2001 Jun 23;357(9273):1992-4 [11438127.001]
  • [Cites] Cell Struct Funct. 2001 Jun;26(3):179-87 [11565810.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):205-9 [11857409.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1152-6 [11948127.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2362-70 [12460779.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1857-67 [12759243.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Pathol. 2003 Dec;201(4):562-72 [14648659.001]
  • [Cites] Science. 2004 Feb 6;303(5659):775-7 [14764858.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7377-85 [15492259.001]
  • [Cites] N Engl J Med. 1986 Aug 28;315(9):559-63 [3736639.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):1127-36 [1720121.001]
  • [Cites] J Cell Physiol. 1992 Mar;150(3):534-44 [1537883.001]
  • [Cites] Lancet. 1992 Jun 13;339(8807):1483 [1351156.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5190-7 [1382837.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Nucleic Acids Res. 1993 Jan 11;21(1):163-8 [7680113.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1039-43 [8096955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10154-8 [7694284.001]
  • [Cites] Development. 1994 Mar;120(3):637-47 [7512896.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):539-48 [7518469.001]
  • [Cites] Mol Biol Cell. 1994 Apr;5(4):439-53 [7519905.001]
  • [Cites] FEBS Lett. 1994 Sep 26;352(2):216-8 [7523186.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8650-4 [7536739.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] FEBS Lett. 1996 Jul 8;389(3):304-8 [8766721.001]
  • [Cites] Mol Biol Cell. 1996 Jun;7(6):883-92 [8816995.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):999-1004 [8855965.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Differentiation. 1997 Nov;62(2):71-82 [9404002.001]
  • [Cites] J Cell Sci. 1998 Apr;111 ( Pt 8):1095-104 [9512505.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1135-42 [9620072.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1345-52 [10329587.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):477-83 [10404058.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Mol Biol Cell. 1999 Sep;10(9):2933-43 [10473637.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4003-11 [15930334.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3200-8 [16707621.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Histopathology. 2007 Mar;50(4):434-8 [17448018.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4615-24 [17855508.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34929-37 [17901052.001]
  • [Cites] Breast Cancer Res. 2007;9(6):404; author reply 405 [18279542.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6942-52 [18757408.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5555-64 [18765548.001]
  • [Cites] Breast Cancer Res. 2009;11(2):R24 [19405959.001]
  • [Cites] J Vis Exp. 2009;(29). pii: 1475. doi: 10.3791/1475 [19620957.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • (PMID = 20678196.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Tenascin
  • [Other-IDs] NLM/ PMC2949648
  •  go-up   go-down


25. Fitzpatrick JM, Banu E, Oudard S: Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int; 2009 Mar;103(5):578-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To this end, much research has been conducted over many years with the goal of identifying a reliable and easily measurable tumour marker that could be used on a large scale for the diagnosis, staging and monitoring of the disease.
  • PSA is now the most widely used serum marker for detecting and monitoring prostate cancer, but its use as a diagnostic marker is controversial because it has several limitations, including its low specificity (PSA levels are also increased in benign prostatic hyperplasia, and in general inflammatory responses) and low sensitivity.
  • [MeSH-major] Neoplasms, Hormone-Dependent / diagnosis. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis


26. Casula M, Alaibac M, Pizzichetta MA, Bono R, Ascierto PA, Stanganelli I, Canzanella S, Palomba G, Zattra E, Italian Melanoma Intergroup (IMI), Palmieri G: Role of the EGF +61A&gt;G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. BMC Dermatol; 2009;9:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls.
  • METHODS: Individuals with less than 10 (N = 127) or more than 100 (N = 128) benign nevi, and patients with cutaneous melanoma (N = 418) were investigated for the EGF +61A>G polymorphism, using an automated sequencing approach.
  • [MeSH-major] Epidermal Growth Factor / genetics. Melanoma / genetics. Polymorphism, Single Nucleotide. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2002 Feb 2;359(9304):397-401 [11844511.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):673-5 [14520709.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2668-72 [15087376.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):755-9 [15373781.001]
  • [Cites] Acta Oncol. 2007;46(8):1113-7 [17851837.001]
  • [Cites] Tumour Biol. 1990;11(5):229-61 [2203137.001]
  • [Cites] J Invest Dermatol. 2006 Oct;126(10):2242-6 [16691190.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):137-43 [17055252.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):760-2 [15373782.001]
  • (PMID = 19624835.001).
  • [ISSN] 1471-5945
  • [Journal-full-title] BMC dermatology
  • [ISO-abbreviation] BMC Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2719594
  • [Investigator] Scarrà GB; Sileni VC; Di Filippo F; Maio M; Parmiani G; Queirolo P; Ridolfi R; Rossi C; Testori A
  •  go-up   go-down


27. de Vries M, Perquin DA: Non-puerperal uterine inversion due to submucous myoma in a young woman: a case report. J Med Case Rep; 2010;4:21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A submucous myoma is mostly the cause of the non-puerperal inversion but diagnosis can be difficult.
  • CASE PRESENTATION: A 19-year-old nulliparous woman presented with abnormal vaginal bleeding, dysmenorrhoea, and a large mass protruding from her cervix.
  • The diagnosis was confirmed and the patient's uterus could be preserved.
  • CONCLUSION: We report a case of non-puerperal uterine inversion associated with a benign submucous myoma.
  • Non-puerperal uterine inversion is very uncommon in women of reproductive age and is usually caused by a malignant tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1989 Mar-Apr;13(2):357-9 [2647797.001]
  • [Cites] Obstet Gynecol. 1968 Sep;32(3):376-81 [5754584.001]
  • [Cites] Br J Obstet Gynaecol. 1982 Mar;89(3):247-9 [7066262.001]
  • [Cites] Am J Surg. 1951 May;81(5):492-5 [14829695.001]
  • [Cites] J Obstet Gynaecol Res. 2008 Aug;34(4 Pt 2):735-8 [18840193.001]
  • [Cites] Int J Clin Oncol. 2006 Apr;11(2):153-5 [16622752.001]
  • [Cites] East Afr Med J. 2006 Mar;83(3):110-3 [16771108.001]
  • [Cites] Obstet Gynecol. 2007 Aug;110(2 Pt 2):491-3 [17666639.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):938-41 [15885762.001]
  • (PMID = 20205761.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2822794
  •  go-up   go-down


28. Halldorsson A, Dissanaike S, Kaye KS: Alveolar adenoma of the lung: a clinicopathological description of a case of this very unusual tumour. J Clin Pathol; 2005 Nov;58(11):1211-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar adenoma of the lung: a clinicopathological description of a case of this very unusual tumour.
  • Alveolar adenomas are extremely rare, and are probably benign lung tumours of unknown histogenesis.
  • Although a positron emission tomography scan seemed to document the benign nature of the lesion, a thoracoscopic wedge resection was performed to alleviate the symptoms and verify the diagnosis.
  • Histologically, the lesion was well demarcated, dominated by large and small cysts with no normal lung parenchyma.
  • [MeSH-major] Adenoma / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2004 Apr;12(2):155-9 [15173924.001]
  • [Cites] Pathologe. 1990 Jan;11(1):48-54 [2179944.001]
  • [Cites] Pathologe. 1996 Mar;17(2):150-3 [8650145.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jul 1;89(1):34-7 [8689607.001]
  • [Cites] Virchows Arch. 1996 Oct;429(2-3):101-8 [8917711.001]
  • [Cites] Virchows Arch. 1997 Feb;430(2):181-4 [9083522.001]
  • [Cites] Pol J Pathol. 2003;54(2):147-52 [14575424.001]
  • [Cites] Cesk Patol. 1997 May;33(2):49-52 [9340215.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):158-67 [10029443.001]
  • [Cites] Hum Pathol. 1986 Oct;17(10):1066-71 [3759064.001]
  • [Cites] Ann Pathol. 1999 Sep;19(4):325-8 [10544770.001]
  • [Cites] J Thorac Imaging. 2002 Apr;17(2):163-6 [11956369.001]
  • [Cites] Rontgenpraxis. 1997 Feb;50(2):29-30 [9173555.001]
  • (PMID = 16254114.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770767
  •  go-up   go-down


29. Daniel A Jr, Ullah E, Wahab S, Kumar V Jr: Relevance of MRI in prediction of malignancy of musculoskeletal system--a prospective evaluation. BMC Musculoskelet Disord; 2009;10:125
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of this study is to evaluate the role of MRI in musculoskeletal tumours, especially, in prediction of malignancy & to compare whether the diagnosis made on MRI correlates with the cytological/histopathological diagnosis.
  • RESULTS: Features associated with benign diagnosis in a large percentage of cases, are size less than 8 cm, sharp margination, homogeneous T2 signal, absence of oedema, necrosis, calcification and fluid-fluid levels.
  • A correct histological diagnosis is reached on the basis of imaging studies alone in 65% to 75% of cases.
  • The sensitivity for a MRI diagnosis of malignant tumour was 95% and specificity was 84%.
  • CONCLUSION: Differentiation of malignant from benign lesions of musculoskeletal system is best made by a combination of clinical and imaging parameters rather than by any single MR characteristic.
  • When a lesion has a non-specific MR imaging appearance, it is useful to formulate a suitably ordered differential diagnosis based on tumour prevalence, patient age, and anatomic location.
  • [MeSH-major] Bone Neoplasms / diagnosis. Magnetic Resonance Imaging / standards. Muscle Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Jun;174(6):1623-8 [10845496.001]
  • [Cites] J Chin Med Assoc. 2003 Nov;66(11):655-61 [14768852.001]
  • [Cites] Br J Radiol. 1990 Apr;63(748):251-6 [2346863.001]
  • [Cites] AJR Am J Roentgenol. 1990 Dec;155(6):1251-5 [2122675.001]
  • [Cites] Radiology. 1992 Nov;185(2):581-6 [1410377.001]
  • [Cites] J Belge Radiol. 1992 Aug;75(4):286-96 [1459930.001]
  • [Cites] Br J Radiol. 1992 Jan;65(769):14-20 [1336692.001]
  • [Cites] Bildgebung. 1993 Mar;60(1):3-9 [8485369.001]
  • [Cites] Australas Radiol. 1993 Feb;37(1):35-9 [8323508.001]
  • [Cites] AJR Am J Roentgenol. 1995 May;164(5):1191-9 [7717231.001]
  • [Cites] Radiographics. 1995 Mar;15(2):349-66 [7761640.001]
  • [Cites] Radiol Med. 1996 Apr;91(4):344-7 [8643841.001]
  • [Cites] Semin Surg Oncol. 1999 Jul-Aug;17(1):2-10 [10402633.001]
  • [Cites] Radiology. 2004 Nov;233(2):493-502 [15459325.001]
  • [Cites] Eur Radiol. 2004 Dec;14(12):2320-30 [15290067.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2922-30 [17013893.001]
  • [Cites] Eur Radiol. 2007 Oct;17(10):2675-86 [17342487.001]
  • (PMID = 19811663.001).
  • [ISSN] 1471-2474
  • [Journal-full-title] BMC musculoskeletal disorders
  • [ISO-abbreviation] BMC Musculoskelet Disord
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2766372
  •  go-up   go-down


30. Koljonen V, Jahkola T, Tukiainen E, Granroth G, Haglund C, Böhling T: Tenascin-C in primary Merkel cell carcinoma. J Clin Pathol; 2005 Mar;58(3):297-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Merkel cell carcinoma (MCC) is a rare malignant cutaneous neuroendocrine tumour that mostly affects the elderly.
  • It shows rapid progression of the primary tumour, together with a vertical growth pattern into the underlying subcutaneous tissue.
  • Tenascin-C (Tn-C) is a large extracellular matrix glycoprotein that is expressed in various benign and malignant processes.
  • The expression of Tn-C correlated significantly with large tumour size.
  • CONCLUSIONS: Tn-C expression seems to increase with tumour size and malignant behaviour.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Merkel Cell / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism. Tenascin / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Division. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jan;31(1):58-62 [10665914.001]
  • [Cites] Nat Med. 1999 Jun;5(6):662-8 [10371505.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Forensic Sci Int. 2002 Apr 18;126(2):118-22 [12084487.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):3051-6 [12926160.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):607-10 [12943628.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):31-40 [14618612.001]
  • [Cites] APMIS. 2004 Jan;112(1):39-44 [14961973.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4587-91 [14981900.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Sci Am. 1986 Jun;254(6):42-51 [3010451.001]
  • [Cites] Dev Biol. 1988 Aug;128(2):245-55 [2456233.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):254-6 [2170468.001]
  • [Cites] Br J Dermatol. 1991 Jan;124(1):13-20 [1704250.001]
  • [Cites] Int J Cancer. 1991 Apr 1;47(6):811-6 [1707033.001]
  • [Cites] Am J Pathol. 1991 Nov;139(5):1143-50 [1719820.001]
  • [Cites] Invasion Metastasis. 1991;11(6):325-31 [1726610.001]
  • [Cites] Development. 1993 Apr;117(4):1183-98 [8404525.001]
  • [Cites] Perspect Dev Neurobiol. 1994;2(1):111-16 [7530137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):315-23 [7836085.001]
  • [Cites] Methods Enzymol. 1994;245:52-61 [7539094.001]
  • [Cites] Int Arch Allergy Immunol. 1995 Aug;107(4):484-90 [7620364.001]
  • [Cites] Int J Cancer. 1996 Dec 20;69(6):445-7 [8980244.001]
  • [Cites] Matrix Biol. 1998 Aug;17(4):305-16 [9749946.001]
  • [Cites] Clin Cancer Res. 1995 Sep;1(9):1035-41 [9816077.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1687-92 [9893653.001]
  • [Cites] Am J Dermatopathol. 1999 Feb;21(1):16-20 [10027519.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):415-21 [10366470.001]
  • [Cites] Surg Neurol. 2000 Sep;54(3):235-40 [11118570.001]
  • (PMID = 15735164.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Tenascin
  • [Other-IDs] NLM/ PMC1770604
  •  go-up   go-down


31. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy].
  • The cholecystectomy results in change of cholic acids flow into intestine.
  • Permanent type of the bile flow provokes the increase of proliferation of colic epithelial cells and increases the risk for development of right-sided colorectal tumors.
  • Meanwhile morphological features of colorectal tumors at the patients with cholecystectomy are still remaining to be clarified.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • 83 tumors and 49 samples of mucosa were immunostained with monoclonal mouse anti-human p53 protein (Dako) and monoclonal mouse anti-human Ki-67 antigen (Novocastra).
  • Thus, in benign colorectal tumors at the patients with retained function of gallbladder intensifying of epithelial cells proliferation is not accompanied with intensifying of apoptosis, and in malignant tumors a complete supression of apoptosis is observed.
  • The retaining of apoptosis in colorectal tumors compensates intensive proliferative activity with expectation of better prognosis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Cholecystectomy. Colon / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Intestinal Mucosa / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


32. Rakha EA, Kandil MA, El-Santawe MG: Gigantic recurrent abdominal desmoid tumour: a case report. Hernia; 2007 Apr;11(2):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gigantic recurrent abdominal desmoid tumour: a case report.
  • Deeply seated fibromatosis or desmoid tumour (DT) is a rare entity characterized by benign proliferation of fibroblasts.
  • Although non-malignant, this tumour can be life-threatening due to its invasive property and high recurrence rate.
  • We report a unique case of a huge recurrent abdominal DT (36 cm in diameter, 25 kg in weight) that caused pressure necrosis and sloughing of the overlying anterior abdominal wall, and produced a large fungating mass protruding outside the abdomen.
  • Although preoperative neoadjuvant therapies were all ineffective, radical surgical removal of the tumour was successful.
  • [MeSH-major] Fibromatosis, Abdominal / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1989 Dec;210(6):765-9 [2531573.001]
  • [Cites] Arch Surg. 1983 Nov;118(11):1318-22 [6639341.001]
  • [Cites] J Orthop Surg (Hong Kong). 2005 Aug;13(2):174-7 [16131682.001]
  • [Cites] J Clin Gastroenterol. 2003 Aug;37(2):186-8 [12869894.001]
  • [Cites] Ann Chir Gynaecol. 1997;86(1):84-6 [9181224.001]
  • [Cites] Can J Surg. 1996 Jun;39(3):247-52 [8640627.001]
  • [Cites] Eur J Surg Oncol. 1999 Oct;25(5):487-97 [10527597.001]
  • [Cites] Hum Reprod. 2000 Feb;15(2):311-3 [10655300.001]
  • [Cites] Am J Surg. 1985 Feb;149(2):215-8 [3970318.001]
  • [Cites] Diagn Mol Pathol. 1997 Apr;6(2):98-101 [9098648.001]
  • [Cites] Am J Clin Pathol. 1982 Jun;77(6):674-80 [7091047.001]
  • [Cites] Fam Cancer. 2001;1(2):111-9 [14574007.001]
  • [Cites] Ann Chir. 1993;47(4):352-9 [8352514.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):798-801 [9221855.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1268-73 [11584198.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):637-45 [9486614.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1270-4 [7519966.001]
  • [Cites] Pol J Pathol. 2006;57(1):5-15 [16739877.001]
  • [Cites] Am J Surg. 1986 Feb;151(2):230-7 [3946757.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1112-4 [16343190.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):659-65 [9336146.001]
  • (PMID = 17149531.001).
  • [ISSN] 1265-4906
  • [Journal-full-title] Hernia : the journal of hernias and abdominal wall surgery
  • [ISO-abbreviation] Hernia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


33. Sri Paran T, Mortell A, Devaney D, Pinter A, Puri P: Mucinous cystadenoma of the ovary in perimenarchal girls. Pediatr Surg Int; 2006 Mar;22(3):224-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To the best of our knowledge, there are only 13 previous cases of benign mucinous cystadenoma (MCA) of the ovary in perimenarchal girls reported in the literature.
  • We present six cases of this rare tumour.
  • We reviewed the charts of six patients who presented with large MCA of the ovary.
  • Ultrasound demonstrated a large multiloculated cystic mass arising from the pelvis reaching the level of the xiphoid.
  • Laparotomy revealed a tumour arising from the left ovary in five patients and from the right ovary in one.
  • Several litres of fluid were aspirated in order to deliver the tumour from the abdomen.
  • Histology revealed benign MCA of the ovary in all cases.
  • Although this tumour is rare, this diagnosis should be considered in 11 to 15-year-old girls presenting with a very large abdominal mass.
  • [MeSH-major] Cystadenoma, Mucinous / epidemiology. Menarche. Ovarian Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Age Factors. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Incidence. Magnetic Resonance Imaging. Ovariectomy. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Annu. 1992;27 Pt 2:281-356 [1316599.001]
  • [Cites] Am J Obstet Gynecol. 1965 Nov 15;93(6):850-66 [4284808.001]
  • [Cites] J Clin Ultrasound. 1990 May;18(4):359-63 [2161005.001]
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):331-5; discussion 331-5 [12632344.001]
  • [Cites] Eur J Radiol. 1993 Nov;17 (3):159-65 [8293741.001]
  • [Cites] J Pediatr Surg. 1992 Apr;27(4):480-4 [1326038.001]
  • [Cites] Ann Chir Gynaecol Fenn Suppl. 1971;177:1-66 [4333640.001]
  • [Cites] South Med J. 1982 Oct;75(10):1265-7 [7123301.001]
  • [Cites] Clin Obstet Gynecol. 1977 Sep;20(3):607-23 [196802.001]
  • [Cites] J Obstet Gynaecol. 2004 Jan;24(1):93-4 [14675997.001]
  • [Cites] Ugeskr Laeger. 2001 Nov 19;163(47):6601-2 [11760544.001]
  • [Cites] Arch Surg. 1993 Aug;128(8):849-53; discussion 853-4 [8343057.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):219-24 [1592292.001]
  • [Cites] Cancer. 1985 May 1;55(9):1958-62 [2983869.001]
  • [Cites] J Pediatr Adolesc Gynecol. 1999 Feb;12(1):27-9 [9929837.001]
  • [Cites] J Med Assoc Thai. 2004 Feb;87(2):113-8 [15061292.001]
  • [Cites] Rev Med Brux. 2000 Jun;21(3):157-9 [10925597.001]
  • [Cites] Cancer. 1973 May;31(5):1031-45 [4735836.001]
  • [Cites] J Chir (Paris). 1993 Dec;130(12 ):525-8 [8163617.001]
  • [Cites] J Pediatr Surg. 2001 Jun;36(6):E6 [11381449.001]
  • [Cites] South Med J. 1988 Apr;81(4):464-8 [2833818.001]
  • [Cites] Gynecol Oncol. 1984 Nov;19(3):290-7 [6500373.001]
  • [Cites] Eur J Pediatr Surg. 2002 Oct;12(5):330-2 [12469261.001]
  • [Cites] Cancer. 1972 Sep;30(3):713-9 [4342408.001]
  • [Cites] J Pediatr Surg. 2001 Mar;36(3):511-5 [11227010.001]
  • (PMID = 16416281.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Tse GM, Chaiwun B, Lau KM, Scolyer R, Lee CS, Karim RZ, Putti TC, Law BK, Lui PC, Tan PH: Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. J Clin Pathol; 2007 Sep;60(9):1051-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Endothelin-1 expression is increased in infiltrating duct carcinoma and is associated with larger tumour size, higher histological grade and lymphovascular permeation.
  • METHOD: A large series of 461 phyllodes tumours (291 benign, 115 borderline malignant and 55 frankly malignant) were evaluated for endothelin-1 expression in both the epithelial cells and stromal cells by immunohistochemistry; results were correlated with the tumour grade.
  • RESULTS: For benign phyllodes tumours, the epithelial staining of endothelin was negative, weak, moderate and strong in 6%, 26%, 15% and 53% of cases respectively; results were 4%, 18%, 19% and 59% respectively for borderline and 6%, 18%, 6% and 70% respectively for frankly malignant tumours.
  • For the stromal staining, the negative, weak, moderate and strong staining was 32%, 19%, 18% and 31% respectively for benign phyllodes, 24%, 13%, 10% and 53% respectively for borderline and 8%, 16%, 17% and 59% respectively for frankly malignant tumours.
  • [MeSH-major] Breast Neoplasms / metabolism. Endothelin-1 / metabolism. Neoplasm Proteins / metabolism. Phyllodes Tumor / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1995 Sep;27(3):205-18 [8522284.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):910-6 [8608483.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nature. 1988 Mar 31;332(6163):411-5 [2451132.001]
  • [Cites] FEBS Lett. 1988 Apr 25;231(2):440-4 [3282927.001]
  • [Cites] J Biol Chem. 1989 May 15;264(14):7856-61 [2542249.001]
  • [Cites] Surg Gynecol Obstet. 1990 Mar;170(3):193-6 [2154867.001]
  • [Cites] J Surg Oncol. 1990 Sep;45(1):46-51 [2166186.001]
  • [Cites] J Exp Med. 1990 Dec 1;172(6):1741-8 [1701822.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):141-7 [1309302.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):720-7 [9973223.001]
  • [Cites] Pathol Res Pract. 1998;194(2):97-104 [9584322.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):4046-9 [1319837.001]
  • [Cites] Eur J Pharmacol. 1999 Jun 30;375(1-3):133-8 [10443571.001]
  • [Cites] Histopathology. 1999 Aug;35(2):162-9 [10460662.001]
  • [Cites] Pathol Int. 1999 Sep;49(9):807-10 [10504552.001]
  • [Cites] Am J Clin Pathol. 2005 Apr;123(4):529-40 [15743740.001]
  • [Cites] Cancer Lett. 2005 May 26;222(2):129-38 [15863261.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1720-8 [15841074.001]
  • [Cites] Surg Oncol. 1995;4(6):309-15 [8809953.001]
  • [Cites] Histopathology. 2000 Feb;36(2):161-7 [10672062.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):51-61 [10708518.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Apr;22(4):422-31 [10745023.001]
  • [Cites] BJU Int. 2000 Apr;85 Suppl 2:45-8 [10781185.001]
  • [Cites] Eur J Immunol. 2002 Sep;32(9):2393-400 [12207323.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):21-8 [12497202.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1273-81 [12516960.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Pathol. 2003 May;200(1):59-64 [12692842.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4125-31 [14519635.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1007-13 [14559983.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2461-8 [15059899.001]
  • [Cites] Mod Pathol. 2004 Jul;17(7):827-31 [15044924.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1053-7 [15343505.001]
  • [Cites] Radiology. 1983 Feb;146(2):481-6 [6294737.001]
  • [Cites] J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S1-4 [11078319.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:851-76 [11264479.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):734-40 [12118111.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):376-9 [8383473.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1252-6 [8393684.001]
  • (PMID = 17158636.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1972415
  •  go-up   go-down


35. Schulz HU, Kellner U, Kahl S, Effenberger O, Asperger W, Lippert H, Röcken C: A giant pancreatic serous microcystic adenoma with 20 years follow-up. Langenbecks Arch Surg; 2007 Mar;392(2):209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: There is only little information about the spontaneous course of large pancreatic serous tumours.
  • CASE REPORT: At first clinical presentation, in 1986, the tumour measured 4.5 cm in diameter.
  • A biopsy was obtained, and the tumour was diagnosed as lymphangioma, based on hematoxylin and eosin-staining.
  • During the follow-up, the tumour progressively increased in size, measuring 12 cm in diameter in 1993 and 17 cm in 2000.
  • A colonic resection was necessary because of compression by the tumour in 1993.
  • Finally, the initial biopsy specimen was re-evaluated, using immunohistochemistry, and the final diagnosis of a serous microcystic adenoma was made.
  • CONCLUSION: This unique case demonstrates that the spontaneous course of serous microcystic adenoma of the pancreas may be favourable even with huge tumour size and that immunohistochemistry may prove a valuable tool for differential diagnosis of cystic pancreatic lesions.
  • Due to their size and progressive, space-occupying growth, these biologically benign tumours may cause injury to adjacent organs and thus clinical symptoms.
  • For this reason, curative surgical resection is the treatment of choice for this tumour entity except for small, asymptomatic lesions, which do not require intervention.
  • [MeSH-major] Cystadenoma, Serous / surgery. Pancreatic Neoplasms / surgery


36. Yu J, Roy D, Brockmeyer AD, Dubeau L: Increased chromosomal stability in cultures of ovarian tumours of low malignant potential compared to cystadenomas. Br J Cancer; 2007 Jun 18;96(12):1908-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell cultures of ovarian cystadenomas transfected with SV40 large T antigen are not immortal because they invariably reach a phenomenon called crisis, which is triggered in part by telomere attrition.
  • Here, we show that in sharp contrast to these benign ovarian tumours, the DNA content of ovarian tumours of low malignant potential (LMP) was remarkably stable as they approached crisis, suggesting that telomere attrition was the main determinant of this mortality checkpoint.
  • Lack of a ploidy-based crisis was not due to loss of expression of a functional SV40 large T antigen protein.
  • This fundamental difference in chromosomal stability between ovarian cystadenomas and LMP tumours also suggests potential differences in predisposition to progression to malignancy between these two ovarian tumour subtypes.


37. Heffernan EJ, Hayes MM, Alkubaidan FO, Clarkson PW, Munk PL: Aggressive angiomyxoma of the thigh. Skeletal Radiol; 2008 Jul;37(7):673-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aggressive angiomyxoma is a rare tumour that typically occurs in the perineum in women of reproductive age.
  • While benign, the tumour is locally infiltrative and consequently has a high rate of local recurrence following surgery; therefore, accurate pre-operative diagnosis is important.
  • We describe a case of aggressive angiomyxoma arising in the thigh of a 54-year-old man, which we believe is the first reported instance of this rare neoplasm occurring remote from the pelvis or perineum in a male patient.
  • At histological analysis, the tumour exhibited the characteristic features of aggressive angiomyxoma, with bland spindle cells and large, hyalinised blood vessels in a hypocellular myxoid matrix.
  • Extensive immunohistochemical staining further supported the diagnosis.
  • While the imaging features of these tumours are non-specific and suggestive of myxoid neoplasms, the diagnosis should be considered whenever biopsy of a myxoid-appearing mass yields hypocellular, non-diagnostic material, despite adequate sampling.
  • [MeSH-major] Magnetic Resonance Imaging. Myxoma / diagnosis. Soft Tissue Neoplasms / diagnosis. Thigh / diagnostic imaging. Thigh / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):559-63 [12943618.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jan-Feb;15(1):140-5 [15670309.001]
  • [Cites] J Gastroenterol. 2002;37(4):303-8 [11993516.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):435-8 [9930798.001]
  • [Cites] J Clin Pathol. 2000 Aug;53(8):603-5 [11002763.001]
  • [Cites] Int J Urol. 2004 Jun;11(6):432-5 [15157218.001]
  • [Cites] Am J Clin Pathol. 1997 Jan;107(1):45-51 [8980366.001]
  • [Cites] Hum Pathol. 1985 Jun;16(6):621-8 [3997139.001]
  • [Cites] Ann Diagn Pathol. 2006 Aug;10(4):197-204 [16844560.001]
  • [Cites] N Engl J Med. 1999 Dec 2;341(23):1772 [10610453.001]
  • [Cites] Clin Radiol. 2003 Feb;58(2):157-62 [12623047.001]
  • [Cites] Urol Int. 1997;58(4):247-9 [9253128.001]
  • [Cites] AJR Am J Roentgenol. 1998 Aug;171(2):530-1 [9694499.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):396-401 [16445665.001]
  • [Cites] Int J Colorectal Dis. 2007 Dec;22(12):1545-6 [17242939.001]
  • [Cites] Radiology. 2007 Feb;242(2):625-7 [17255431.001]
  • [Cites] Abdom Imaging. 2006 May-Jun;31(3):383-6 [16317491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):1072-4 [14608546.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Nov;62(11):1429-31 [15510368.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:356-60 [16515622.001]
  • [Cites] Am J Surg Pathol. 1983 Jul;7(5):463-75 [6684403.001]
  • [Cites] Ultrastruct Pathol. 2006 May-Jun;30(3):193-205 [16825121.001]
  • [Cites] J Clin Ultrasound. 2001 Oct;29(8):476-8 [11745856.001]
  • [Cites] Histopathology. 1997 Jan;30(1):3-10 [9023551.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):79-90 [8646730.001]
  • (PMID = 18338163.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Hauenschild L, Bader FG, Laubert T, Czymek R, Hildebrand P, Roblick UJ, Bruch HP, Mirow L: Laparoscopic colorectal resection for benign polyps not suitable for endoscopic polypectomy. Int J Colorectal Dis; 2009 Jul;24(7):755-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colorectal resection for benign polyps not suitable for endoscopic polypectomy.
  • BACKGROUND AND AIMS: Endoscopic polypectomy still remains the cornerstone of therapy for colorectal polyps and adenomas.
  • However, if colorectal polyps are too large or not accessible for endoscopic ablation or cannot be removed without an increased risk for perforation, operative procedures are required.
  • In patients which could not be treated by endoscopic polypectomy due to size, location, and/or risk of complications, a laparoscopic colorectal resection was performed.
  • All data were prospectively assessed in our "colorectal resection" database.
  • RESULTS: The database analysis revealed 58 patients with endoscopically not resectable colorectal polyps who underwent a laparoscopic colorectal resection (intend to treat).
  • The histopathological work-up revealed benign disease in all cases.
  • CONCLUSION: Laparoscopic resection of colorectal polyps is a safe and minimally invasive technique for the management of benign colorectal tumors.
  • [MeSH-major] Colonic Polyps / pathology. Colonic Polyps / surgery. Colorectal Surgery. Endoscopy. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):39-42 [14718273.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Chirurg. 2003 Oct;74(10):966-80; quiz 981-2 [15017996.001]
  • [Cites] Rev Esp Enferm Dig. 2004 May;96(5):315-21 [15180443.001]
  • [Cites] J Gastrointest Surg. 2009 Feb;13(2):275-81 [18941844.001]
  • [Cites] World J Surg. 2002 Mar;26(3):377-83 [11865378.001]
  • [Cites] Surg Endosc. 1997 Jun;11(6):643-4 [9171124.001]
  • [Cites] Surg Endosc. 2003 Sep;17(9):1461-3 [12739115.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1380-3 [14530679.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):34-41 [16012932.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s243-7 [15666099.001]
  • [Cites] Cancer. 1989 Nov 1;64(9):1937-47 [2477139.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s283-90 [15666108.001]
  • [Cites] Br J Surg. 1993 Jun;80(6):788-93 [8330178.001]
  • [Cites] Surg Endosc. 1997 Feb;11(2):119-22 [9069140.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1246-9 [11005491.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):746-8 [11357040.001]
  • [Cites] Ann Surg. 2008 Jul;248(1):1-7 [18580199.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s291-4 [15666109.001]
  • [Cites] Onkologie. 2001 Feb;24(1):29-32 [11441277.001]
  • [Cites] Mayo Clin Proc. 2000 Apr;75(4):344-8 [10761487.001]
  • [Cites] Dig Dis. 2005;23(2):127-34 [16352892.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):234-41 [15278051.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):116-20 [11285950.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 19283390.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Chakraborty S, Swanson BJ, Bonthu N, Batra SK: Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases. J Clin Pathol; 2010 Jul;63(7):579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases.
  • MUC4, a large transmembrane mucin, has recently emerged as a novel marker for diagnosis, prognosis and therapy in several malignancies.
  • METHODS: A total of 330 tissue spots representing the normal skin, and benign and malignant cutaneous diseases, were analysed after staining with the monoclonal antibody to human MUC4 (clone 8G7).
  • RESULTS: While the normal epidermis showed a negative to weak-positive expression of MUC4, its expression was significantly upregulated in squamous cell carcinomas (SCCs) where the intensity of staining correlated negatively with tumour grade and positively with age.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7 [10607349.001]
  • [Cites] Int J Gynecol Pathol. 2009 Mar;28(2):127-33 [19188823.001]
  • [Cites] Dermatol Clin. 2000 Apr;18(2):xv-xxi [10791144.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Microbes Infect. 2002 Sep;4(11):1121-4 [12361911.001]
  • [Cites] Pancreas. 2003 Apr;26(3):e48-54 [12657964.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Hepatology. 2004 Jan;39(1):220-9 [14752841.001]
  • [Cites] Histopathology. 1984 May;8(3):423-34 [6329942.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):806-13 [15897748.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):421-9 [16302265.001]
  • [Cites] Dig Dis Sci. 2006 Feb;51(2):381-9 [16534686.001]
  • [Cites] J Dermatol. 2006 May;33(5):309-18 [16700662.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):556-62 [17425384.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):309-20 [17406026.001]
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2065-70 [18381409.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1540-7 [18392050.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):520-6 [18665193.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):949-56 [18781152.001]
  • [Cites] J Biosci. 2009 Mar;34(1):113-23 [19430123.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Jan;41(1):82-8 [10634605.001]
  • (PMID = 20591909.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590-13; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / R01 CA78590; United States / NCI NIH HHS / CA / P50 CA127297; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA131944; United States / NCI NIH HHS / CA / R01 CA 133774; United States / NCI NIH HHS / CA / R01 CA133774
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS224552; NLM/ PMC2920126
  •  go-up   go-down


40. Pedamallu SB, Murphy J, Boyd D, Martin-Hirsch D, Al-Zwae K: Direct intracranial extension of malignant eccrine spiradenoma of the face. J Clin Med Res; 2009 Aug;1(3):181-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are aggressive tumours normally arising in long-standing benign eccrine spiradenomas.
  • A 48 years old woman presented with a large exophytic tumour on the right side of her face.
  • She underwent craniotomy and debulking of the right temporal lobe and biopsy of the facial tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22493654.001).
  • [ISSN] 1918-3003
  • [Journal-full-title] Journal of clinical medicine research
  • [ISO-abbreviation] J Clin Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3318883
  •  go-up   go-down


41. Kelley SP, Ashford RU, Rao AS, Dickson RA: Primary bone tumours of the spine: a 42-year survey from the Leeds Regional Bone Tumour Registry. Eur Spine J; 2007 Mar;16(3):405-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone tumours of the spine: a 42-year survey from the Leeds Regional Bone Tumour Registry.
  • We conducted a review of the Leeds Regional Bone Tumour Registry for primary bone tumours of the spine since establishment in 1958 until year 2000.
  • The Leeds Bone Tumour Registry was reviewed and a total of 2,750 cases of bone tumours and tumour-like cases were analysed.
  • Chordoma was the most frequent tumour in the cervical and sacral regions, while the most common diagnosis overall was multiple myeloma and plasmacytoma.
  • The mean age of presentation was 42 years and pain was the most common presenting symptom, occurring in 95% of malignant and 76% of benign tumours.
  • The establishment of Bone Tumour Registries is the only way that sufficient data on large numbers of these rare tumours can be accumulated to provide a valuable and otherwise unavailable source of information for research, education and clinical follow-up.
  • [MeSH-major] Chordoma / pathology. Multiple Myeloma / pathology. Osteosarcoma / pathology. Plasmacytoma / pathology. Registries / statistics & numerical data. Spinal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1986 Apr;68(4):483-94 [3957973.001]
  • [Cites] Spine (Phila Pa 1976). 1987 Nov;12(9):843-51 [3441830.001]
  • [Cites] Spine (Phila Pa 1976). 1990 Feb;15(2):137-40 [2326708.001]
  • [Cites] Int Orthop. 1994 Jun;18(3):180-3 [7927969.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Pathology. 2005 Aug;37(4):278-83 [16194825.001]
  • [Cites] Neurochirurgia (Stuttg). 1982 Sep;25(5):153-64 [7155253.001]
  • [Cites] J Bone Joint Surg Am. 1967 Jan;49(1):111-21 [6015754.001]
  • [Cites] J Bone Joint Surg Br. 1974 Aug;56B(3):534-40 [4529234.001]
  • [Cites] J Bone Joint Surg Br. 1976 May;58(2):202-11 [932083.001]
  • [Cites] Br J Cancer. 1977 Oct;36(4):511-22 [271010.001]
  • [Cites] J Bone Joint Surg Br. 1978 Aug;60-B(3):406-11 [681419.001]
  • [Cites] Cancer. 1980 Aug 1;46(3):595-604 [6930985.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):1-11 [11227920.001]
  • (PMID = 16865376.001).
  • [ISSN] 0940-6719
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2200710
  •  go-up   go-down


42. Hardell L, Carlberg M: Mobile phones, cordless phones and the risk for brain tumours. Int J Oncol; 2009 Jul;35(1):5-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The questionnaire was answered by 905 (90%) cases with malignant brain tumours, 1,254 (88%) cases with benign tumours and 2,162 (89%) population-based controls.
  • Anatomical area in the brain for the tumour was assessed and related to side of the head used for both types of wireless phones.
  • In the current analysis we defined ipsilateral use (same side as the tumour) as >or=50% of the use and contralateral use (opposite side) as <50% of the calling time.
  • However, the medical diagnosis and treatment of this tumour type has changed during recent years and underreporting from a single center would have a large impact for such a rare tumour.
  • [MeSH-major] Brain Neoplasms / etiology. Cell Phones. Microwaves / adverse effects. Neoplasms, Radiation-Induced / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19513546.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


43. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol; 2005 Sep;27(3):225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
  • AIM: To analyze vascular endothelial growth factor (VEGF), c-erbB-2 and c-erbB-3 expression and to evaluate their relation to clinicopathologic parameters and pathogenesis of colorectal carcinoma.
  • METHODS: Sections of adenoma, intramucosal carcinoma and adenocarcinoma were evaluated by immunohistochemistry in 85 malignant and 37 benign colorectal neoplasms for the expression of VEGF, c-erbB-2 and c-erbB-3 considering clinicopathological variables.
  • RESULTS: VEGF was detected in comparable percentages of all neoplasm types while c-erbB-2 expression was detectable more frequently in adenoma than adenocarcinoma cases (65% vs 43%).
  • Except for the correlation of c-erbB-3 expression with Dukes' staging, there was no correlation between the studied markers and grade of differentiation, Dukes' stage and localization of colorectal adenocarcinoma. c-erbB-3 expression was seen more frequently in tubular adenomas, while c-erbB-2 expression was higher in tubulovillous and villous types.
  • CONCLUSION: These results suggest that VEGF, c-erbB-2, c-erbB-3 expression does not have prognostic value in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-3 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244586.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


44. Bordi C, D'Adda T, Azzoni C, Pizzi S, Bottarelli L, Mormandi F, Antonetti T, Luong TV, Rindi G: Criteria for malignancy in gastrointestinal endocrine tumors. Endocr Pathol; 2006;17(2):119-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for malignancy in gastrointestinal endocrine tumors.
  • In contrast with the large amount of data generated from endocrine tumors of the pancreas, sparse and mostly unconfirmed data are available on the criteria for the assessment of malignancy risk and patient outcome in endocrine tumors of the gastrointestinal tract.
  • In these conditions the 2000 WHO classification with its standardized scheme of pathologic report constitutes a framework facilitating the assessment of tumor malignancy and has been regarded as useful for clinical purposes, providing the basis for proper management of the patients and for the design of treatment protocols.
  • The classification is based on a combination of pathological and clinical features with parameters specific for each organ in which the endocrine tumors originate.
  • (1) well-differentiated endocrine tumors, further subdivided into tumors with benign and with uncertain behavior;.
  • In this review the differential tumor characteristics between the different categories are summarized.
  • Moreover, the relevance of additional features with respect to tumor prognostication, chiefly the Ki-67 proliferation index and malignancy-associated genetic changes, is discussed with emphasis on the discrepancies emerging between tumors of foregut and of midgut origin.
  • [MeSH-major] Endocrine Gland Neoplasms / classification. Endocrine Gland Neoplasms / diagnosis. Gastrointestinal Neoplasms / classification. Gastrointestinal Neoplasms / diagnosis. Neoplasm Invasiveness / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Ki-67 Antigen. Mitotic Index. Prognosis. World Health Organization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Histopathology. 2004 Oct;45(4):384-92 [15469477.001]
  • [Cites] World J Surg. 1998 Mar;22(3):309-18 [9494425.001]
  • [Cites] Q J Nucl Med. 2000 Mar;44(1):3-12 [10932597.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1903-11 [11395364.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1787-94 [10595906.001]
  • [Cites] Tumour Biol. 1992;13(1-2):27-35 [1317054.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1094-101 [11679944.001]
  • [Cites] J Pathol. 2002 Apr;196(4):401-7 [11920735.001]
  • [Cites] Yale J Biol Med. 1998 May-Aug;71(3-4):273-84 [10461358.001]
  • [Cites] Cancer. 1971 Oct;28(4):990-8 [4106849.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):285-92 [11196176.001]
  • [Cites] Virchows Arch. 1996 Dec;429(6):323-33 [8982376.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Dec;32(4):364-72 [11746977.001]
  • [Cites] Hum Pathol. 1988 May;19(5):580-5 [2453443.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1803-8 [11337378.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):258-64 [10502325.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):706-11 [14608896.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1273-82 [12973852.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1145-53 [15316313.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;413(5):387-98 [2845642.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1765-75 [15755998.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):311-5 [9927038.001]
  • [Cites] J Pathol. 1998 Sep;186(1):41-50 [9875139.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):532-42 [10029611.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:1-12 [15153415.001]
  • [Cites] Am J Pathol. 1989 Dec;135(6):1065-72 [2480712.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] J Pathol. 1998 Aug;185(4):389-93 [9828837.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):472-8 [11257621.001]
  • [Cites] Cancer. 1983 Jan 15;51(2):277-82 [6821817.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S8-19 [7762739.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;419(6):463-8 [1750193.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):532-8 [11920612.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):404-10 [9218518.001]
  • [Cites] J Pathol. 1999 Nov;189(3):394-401 [10547602.001]
  • [Cites] J Pathol. 2001 Aug;194(4):451-8 [11523053.001]
  • [Cites] J Pathol. 2005 Aug;206(4):409-16 [15887288.001]
  • [Cites] Am J Clin Pathol. 1990 Feb;93(2):273-6 [1689098.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):437-50 [14713256.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • [Cites] Expert Rev Mol Diagn. 2001 Sep;1(3):323-33 [11901838.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):947-57 [14871972.001]
  • (PMID = 17159244.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  • [Number-of-references] 51
  •  go-up   go-down


45. Nonn L, Ananthanarayanan V, Gann PH: Evidence for field cancerization of the prostate. Prostate; 2009 Sep 15;69(13):1470-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Field cancerization, which is not yet well-characterized in the prostate, occurs when large areas of an organ or tissue surface are affected by a carcinogenic insult, resulting in the development of multi-focal independent premalignant foci and molecular lesions that precede histological change.
  • In addition to comparing cancer-adjacent benign tissue to more distant areas or to "supernormal" tissue from cancer-free organs, investigators can use a nested case-control design for negative biopsies that offers a number of unique advantages.
  • CONCLUSIONS: True carcinogenic field effects should be distinguished from secondary responses of the microenvironment to a developing tumor, although the latter may still lead to useful clinical prediction tools.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Jun 1;99(4):549-54 [11992544.001]
  • [Cites] BJU Int. 2008 Aug;102(3):364-70 [18410440.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6405-9 [12438224.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):1978-87 [12673203.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5401-6 [12702759.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):540-52 [14755684.001]
  • [Cites] J Urol. 2004 Apr;171(4):1419-23 [15017188.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3465-73 [15161703.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11428-31 [15280533.001]
  • [Cites] Mol Cancer Res. 2004 Sep;2(9):489-94 [15383627.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6572-8 [15475446.001]
  • [Cites] Cancer. 1995 May 15;75(10):2545-51 [7537624.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):824-8 [7635445.001]
  • [Cites] Tumour Biol. 1996;17(1):58-64 [7501974.001]
  • [Cites] Eur Urol. 1996;30(2):191-200 [8875200.001]
  • [Cites] Hum Pathol. 1997 Feb;28(2):143-8 [9023393.001]
  • [Cites] J Pathol. 1997 Aug;182(4):442-9 [9306966.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2133-7 [9329980.001]
  • [Cites] J Urol. 1998 Oct;160(4):1533-9 [9751408.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):1995-2002 [9806659.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5835-41 [9865743.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Feb;24(2):127-34 [9885979.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):569-76 [10100708.001]
  • [Cites] Prostate. 1999 Sep 15;41(1):12-9 [10440871.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4784-7 [10519384.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] J Pathol Bacteriol. 1954 Oct;68(2):617-21 [14354565.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4097-100 [15899799.001]
  • [Cites] J Mol Histol. 2005 Mar;36(3):159-65 [15900405.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] BMC Cancer. 2005;5:45 [15892885.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1985-92 [10595928.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(11):1372-80 [11435067.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8617-23 [11751373.001]
  • [Cites] J Urol. 2005 Aug;174(2):514-8 [16006883.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19093-6 [16361440.001]
  • [Cites] Mol Cancer Res. 2006 Jan;4(1):1-8 [16446401.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] Diagn Cytopathol. 2006 May;34(5):317-22 [16604550.001]
  • [Cites] BMC Cancer. 2006;6:73 [16545117.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1082-7 [16557596.001]
  • [Cites] J Mol Diagn. 2006 Jul;8(3):312-9 [16825503.001]
  • [Cites] Expert Rev Mol Diagn. 2006 Nov;6(6):803-9 [17140367.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] Prostate. 2007 May 1;67(6):638-44 [17342751.001]
  • [Cites] J Urol. 2007 May;177(5):1736-40 [17437801.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):657-66 [17875519.001]
  • [Cites] Breast Cancer Res Treat. 2007 Nov;106(1):75-84 [17221152.001]
  • [Cites] Mod Pathol. 2007 Nov;20(11):1121-7 [17873893.001]
  • [Cites] Prostate. 2008 Feb 1;68(2):152-60 [18058812.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):67-75 [18065961.001]
  • [Cites] BJU Int. 2008 Mar;101(6):765-74 [18190638.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3380-5 [18519767.001]
  • [Cites] PLoS One. 2008;3(10):e3617 [18974881.001]
  • [Cites] J Clin Oncol. 2010 Apr 1;28(10):1714-20 [20177031.001]
  • [Cites] J Invest Dermatol. 2002 Aug;119(2):522-6 [12190879.001]
  • (PMID = 19462462.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090759; United States / NCI NIH HHS / CA / R03 CA131595; United States / NCI NIH HHS / CA / R01 CA90759
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers
  • [Number-of-references] 59
  • [Other-IDs] NLM/ NIHMS482768; NLM/ PMC3690597
  •  go-up   go-down


46. Johnston AJ, Andrews CT: Fibular lengthening by Ilizarov method secondary to shortening by osteochondroma of distal tibia. Strategies Trauma Limb Reconstr; 2008 Apr;3(1):45-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteochondroma is the most common benign bone tumour.
  • A 12-year-old girl presented with a 3-year history of a large swelling affecting the lateral aspect of the right distal tibia.
  • Plain radiographs confirmed a large sessile osteochondroma arising from the postero-lateral aspect of the distal tibia with deformity of the fibula and 15 mm of fibular shortening.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2000 Sep;82(9):1269-78 [11005518.001]
  • [Cites] J Foot Ankle Surg. 2003 Mar-Apr;42(2):95-8 [12701078.001]
  • [Cites] J Int Med Res. 1996 Jul-Aug;24(4):381-6 [8854294.001]
  • [Cites] Acta Orthop Scand. 1990 Oct;61(5):469-70 [2239177.001]
  • [Cites] J Pediatr Orthop. 1989 Jul-Aug;9(4):427-32 [2732323.001]
  • [Cites] J Bone Joint Surg Am. 1977 Mar;59(2):169-73 [403191.001]
  • [Cites] Clin Orthop Relat Res. 1997 Dec;(345):195-7 [9418640.001]
  • [Cites] J Bone Joint Surg Am. 1996 Jan;78(1):20-9 [8550675.001]
  • [Cites] Clin Orthop Relat Res. 1981 Mar-Apr;(155):105-7 [7226604.001]
  • (PMID = 18427924.001).
  • [ISSN] 1828-8936
  • [Journal-full-title] Strategies in trauma and limb reconstruction (Online)
  • [ISO-abbreviation] Strategies Trauma Limb Reconstr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2291477
  •  go-up   go-down


47. Nabarra B, Pontoux C, Godard C, Osborne-Pellegrin M, Ezine S: Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice). Int J Exp Pathol; 2005 Dec;86(6):397-413
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using several techniques, we have assessed morphological characteristics of a malignant thymic tumour in SV12 transgenic (Tg) mice expressing SV40 T and t antigens under control of an L-PK promoter.
  • We describe the development of a carcinoma originating from thymic hyperplasia and followed by the formation of a benign tumour composed chiefly of medullary epithelial cells expressing the transgene and of lymphocytes, a pathology very rarely reported in mice.
  • Our study of the SV12 Tg mice represents the first description of a model of a pure malignant thymic tumour associated with extensive angiogenesis maintained in numerous descendants.
  • The formation of a large tumoral neovascular network, observed here, has never been described in human and/or experimental thymic tumours.
  • [MeSH-major] Antigens, Polyomavirus Transforming / genetics. Antigens, Viral, Tumor / genetics. Neovascularization, Pathologic. Promoter Regions, Genetic. Pyruvate Kinase / genetics. Thymus Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Immunohistochemistry / methods. Male. Mice. Mice, Inbred CBA. Mice, Transgenic. Microscopy, Immunoelectron. Thymus Gland / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thymus. 1993 Aug;22(1):13-33 [7508157.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):409-16 [8123467.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2686-98 [8139568.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3979-83 [8171023.001]
  • [Cites] Prog Growth Factor Res. 1994;5(1):89-97 [7515293.001]
  • [Cites] Histopathology. 1994 Jul;25(1):21-9 [7959642.001]
  • [Cites] Int Rev Cytol. 1995;159:113-60 [7537724.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):127-37 [8534862.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] J Pathol. 1995 Nov;177(3):309-15 [8551394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5742-6 [8650163.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cancer Metastasis Rev. 1995 Dec;14(4):263-77 [8821090.001]
  • [Cites] Cancer Lett. 1996 Oct 22;107(2):293-300 [8947527.001]
  • [Cites] Cell. 1997 Jun 13;89(6):981-90 [9200616.001]
  • [Cites] Science. 1997 Jul 4;277(5322):48-50 [9229772.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] Lab Invest. 1990 Jun;62(6):690-6 [1694254.001]
  • [Cites] Lab Invest. 1990 Sep;63(3):298-306 [1697637.001]
  • [Cites] Anticancer Res. 1990 Sep-Oct;10(5A):1335-9 [1700664.001]
  • [Cites] Annu Rev Physiol. 1991;53:217-39 [1710435.001]
  • [Cites] Exp Pathol. 1990;40(4):301-12 [2098275.001]
  • [Cites] Eur J Cancer. 1991;27(6):781-5 [1712608.001]
  • [Cites] Virchows Arch. 1998 Jan;432(1):33-42 [9463585.001]
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] Dev Comp Immunol. 2001 Apr;25(3):231-43 [11164888.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):635-42 [12068292.001]
  • [Cites] Immunity. 2002 Jun;16(6):803-14 [12121662.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):2842-5 [12218095.001]
  • [Cites] Mol Aspects Med. 2002 Dec;23(6S):S1-27 [12537983.001]
  • [Cites] Dev Immunol. 2002 Dec;9(4):223-31 [15144019.001]
  • [Cites] Cancer Res. 1975 Oct;35(10):2771-9 [1157049.001]
  • [Cites] Nature. 1979 Mar 15;278(5701):261-3 [218111.001]
  • [Cites] J Mol Biol. 1981 Dec 25;153(4):933-59 [6177862.001]
  • [Cites] Am J Clin Pathol. 1982 Oct;78(4):500-7 [6182789.001]
  • [Cites] Cell. 1982 Sep;30(2):361-72 [6183000.001]
  • [Cites] Differentiation. 1983;23(3):256-69 [6189757.001]
  • [Cites] Pathol Res Pract. 1982;175(2-3):256-65 [6190148.001]
  • [Cites] Am J Pathol. 1984 Jan;114(1):121-30 [6197886.001]
  • [Cites] J Pathol. 1983 Nov;141(3):385-413 [6198502.001]
  • [Cites] Lab Invest. 1984 Jan;50(1):36-41 [6198559.001]
  • [Cites] Cell. 1984 Jun;37(2):367-79 [6327063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11822-7 [9751749.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1474-81 [9850173.001]
  • [Cites] Semin Diagn Pathol. 1999 Feb;16(1):2-17 [10355650.001]
  • [Cites] Pathology. 1998 May;30(2):111-22 [9643488.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7533-7 [8356051.001]
  • [Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5797-804 [6209004.001]
  • [Cites] Lab Invest. 1985 Jan;52(1):31-8 [2578201.001]
  • [Cites] Lab Invest. 1985 Mar;52(3):243-56 [2579289.001]
  • [Cites] Mol Cell Biol. 1985 Apr;5(4):642-8 [2985963.001]
  • [Cites] J Natl Cancer Inst. 1985 Aug;75(2):369-79 [3860689.001]
  • [Cites] Nature. 1985 Aug 1-7;316(6027):457-60 [2991771.001]
  • [Cites] Lab Invest. 1986 Nov;55(5):521-30 [2430138.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] J Virol. 1987 Jun;61(6):2029-32 [3033329.001]
  • [Cites] Thymus. 1987;9(2):95-121 [3296336.001]
  • [Cites] Mol Cell Biol. 1987 Sep;7(9):3178-84 [3118193.001]
  • [Cites] EMBO J. 1987 Sep;6(9):2699-704 [2824189.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 May;85(9):3135-9 [2452444.001]
  • [Cites] J Comp Pathol. 1988 Aug;99(2):187-203 [2846660.001]
  • [Cites] Toxicol Pathol. 1988;16(3):321-6 [3194653.001]
  • [Cites] Cell Tissue Res. 1988 Oct;254(1):225-31 [2461804.001]
  • [Cites] Oncogene Res. 1988;3(1):87-97 [3060799.001]
  • [Cites] Annu Rev Genet. 1988;22:479-519 [3071256.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cell. 1989 Sep 8;58(5):803-5 [2673531.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6108-17 [2551499.001]
  • [Cites] Am J Pathol. 1989 Oct;135(4):679-95 [2552813.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1470-8 [2478587.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Am J Surg Pathol. 1990 Feb;14(2):151-66 [1689123.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2417-26 [1693532.001]
  • [Cites] Semin Immunol. 1990 Jan;2(1):13-24 [1717051.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1161-7 [1957168.001]
  • [Cites] J Clin Invest. 1992 Jan;89(1):244-53 [1729274.001]
  • [Cites] Mol Biol Cell. 1992 Feb;3(2):211-20 [1550962.001]
  • [Cites] Development. 1992 Feb;114(2):521-32 [1592003.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Oncogene. 1992 Nov;7(11):2175-87 [1279498.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):99-105 [7677978.001]
  • [Cites] Cancer Treat Res. 1992;63:359-71 [1284027.001]
  • [Cites] Cell. 1993 Mar 26;72(6):835-46 [7681362.001]
  • [Cites] FASEB J. 1993 Jul;7(10):866-71 [8344486.001]
  • [Cites] Toxicol Pathol. 1993;21(2):206-18 [8210943.001]
  • [Cites] Immunol Today. 1993 Sep;14(9):445-59 [8216723.001]
  • [Cites] Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24 [8281615.001]
  • (PMID = 16309545.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Antigens, Viral, Tumor; 0 / Biomarkers, Tumor; EC 2.7.1.40 / Pyruvate Kinase
  • [Other-IDs] NLM/ PMC2517450
  •  go-up   go-down


48. Rochester M, Scurrell S, Parry JR: Prospective evaluation of a novel one-stop testicular clinic. Ann R Coll Surg Engl; 2008 Oct;90(7):565-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, it was possible for patients with unsuspected malignancy to have their diagnosis delayed.
  • Source of referral, suspected diagnosis, findings and outcome were recorded.
  • Eleven patients were suspected to have testicular tumour on ultrasound and proceeded to orchidectomy in this period.
  • CONCLUSIONS: The majority of patients passing through this clinic are the 'worried-well' with benign scrotal pathology.
  • They can now be seen within 2 weeks regardless of whether their GP suspects testicular tumour.
  • This reduces anxiety in this large group of patients freeing capacity elsewhere in the diagnostic imaging department.
  • [MeSH-minor] Adult. England. Humans. Male. Medical Audit. Orchiectomy / utilization. Prospective Studies. Referral and Consultation. Testicular Neoplasms / surgery. Treatment Outcome. Waiting Lists

  • MedlinePlus Health Information. consumer health - Testicular Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann R Coll Surg Engl. 2000 May;82(3):167-70 [10858677.001]
  • [Cites] Ann R Coll Surg Engl. 2006 Jul;88(4):363-6 [16834856.001]
  • [Cites] Int J Clin Pract. 2002 Jan-Feb;56(1):26-8 [11833552.001]
  • [Cites] Postgrad Med J. 2002 Dec;78(926):748-51 [12509694.001]
  • [Cites] J R Soc Med. 2004 Jun;97(6):279-81 [15173329.001]
  • [Cites] Clin Radiol. 1992 Dec;46(6):397-400 [1493653.001]
  • [Cites] Br J Urol. 1994 Feb;73(2):147-51 [8131015.001]
  • [Cites] Br J Urol. 1994 Feb;73(2):152-4 [8131016.001]
  • [Cites] Postgrad Med J. 1997 Mar;73(857):129-36 [9135826.001]
  • [Cites] J Urol. 1997 Aug;158(2):479-80 [9224328.001]
  • [Cites] Colorectal Dis. 2005 May;7(3):241-4 [15859961.001]
  • [Cites] Colorectal Dis. 2005 Sep;7(5):450-3 [16108880.001]
  • [Cites] Int J Clin Pract. 2005 Nov;59(11):1334-9 [16236089.001]
  • [Cites] Postgrad Med J. 2005 Nov;81(961):728-30 [16272239.001]
  • [Cites] BJU Int. 2000 Jul;86(1):87-8 [10886089.001]
  • (PMID = 18701008.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2728304
  •  go-up   go-down


49. Doddi S, Singhal T, Leake T, Sinha P: Management of an incidentally found large adrenal myelolipoma: a case report. Cases J; 2009;2:8414
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of an incidentally found large adrenal myelolipoma: a case report.
  • Adrenal myelolipoma is a rare benign neoplasm composed of mature adipose and hematopoietic tissue.
  • We would like to present a case report of this rare tumour.
  • Cross-sectional imaging is helpful in making a pre-operative diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2004 Jun;11(6):416-8 [15157212.001]
  • [Cites] World J Surg Oncol. 2008;6:72 [18601731.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1373-85 [9397452.001]
  • [Cites] Endocr Pract. 2007 Oct;13(6):667-71 [17954426.001]
  • [Cites] JBR-BTR. 2008 May-Jun;91(3):90-1 [18661711.001]
  • (PMID = 19918428.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769438
  •  go-up   go-down


50. de Vries IA, van Acht MM, Demeyere T, Lybeert ML, de Zoete JP, Nieuwenhuijzen GA: Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature. Radiat Oncol; 2010;5:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Castleman disease (CD) is a rare benign disorder characterised by hyperplasia of lymphoid tissue that may develop at a single site or throughout the body.
  • The etiology of this disorder is unclear, although the histopathological presentation can be differentiated into a hyaline vascular variant, a plasma cell variant and a mixed variant.
  • Surgery remains the main treatment for resectable unicentric CD, since removal of the large node is possible without further complications.
  • Computed tomography (CT)- examination revealed a tumour, which had grown to form a close relationship with the common iliac vessels and the sacral bone.
  • A Laparotomy procedure revealed that the tumour was an irresectable mass.
  • Neo-adjuvant radiotherapy (40 Gy) was administered in order to downsize the tumour.
  • Six weeks later a new CT-scan revealed a major reduction of the tumour, which enabled a successful radical resection of the tumour to be performed.
  • Histopathological analysis of the tumour showed the hyaline vascular type of CD.

  • Genetic Alliance. consumer health - Castleman's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1979 Aug;44(2):457-62 [476562.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):808-10 [6821846.001]
  • [Cites] Hum Pathol. 1985 Mar;16(3):202-5 [3871724.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):876-9 [4016679.001]
  • [Cites] Semin Diagn Pathol. 1988 Nov;5(4):346-64 [2464187.001]
  • [Cites] Surgery. 1989 Nov;106(5):884-7 [2683174.001]
  • [Cites] Ophthalmology. 1989 Nov;96(11):1646-9 [2616150.001]
  • [Cites] Br J Radiol. 1990 Aug;63(752):648-50 [2400884.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):278-83 [1906369.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1365-72 [1873789.001]
  • [Cites] Strahlenther Onkol. 1992 May;168(5):297-9 [1598666.001]
  • [Cites] Surgery. 1992 Nov;112(5):850-5 [1440235.001]
  • [Cites] Mod Pathol. 1992 Sep;5(5):525-30 [1285353.001]
  • [Cites] J Pediatr Surg. 1995 May;30(5):745-7 [7623245.001]
  • [Cites] Mayo Clin Proc. 1995 Oct;70(10):969-77 [7564550.001]
  • [Cites] Cancer Treat Rev. 1995 Jul;21(4):291-310 [7585657.001]
  • [Cites] Ann Hematol. 1996 Jul;73(1):47-50 [8695726.001]
  • [Cites] Ann Intern Med. 1998 Apr 15;128(8):657-62 [9537940.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):706-17 [10091744.001]
  • [Cites] N Engl J Med. 1954 Sep 2;251(10):396-400 [13194083.001]
  • [Cites] Cancer. 1956 Jul-Aug;9(4):822-30 [13356266.001]
  • [Cites] Br J Haematol. 2005 Apr;129(1):3-17 [15801951.001]
  • [Cites] Curr Treat Options Oncol. 2005 May;6(3):255-66 [15869736.001]
  • [Cites] Acta Oncol. 2006;45(8):1126-31 [17118850.001]
  • [Cites] J Clin Oncol. 2007 Mar 10;25(8):971-7 [17350946.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1515-6 [17235715.001]
  • [Cites] Cancer Treat Res. 2008;142:293-330 [18283792.001]
  • [Cites] Ann Surg. 2008 Aug;248(2):243-51 [18650634.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):670-6 [11505414.001]
  • [Cites] Intern Med. 2001 Sep;40(9):976-7 [11579970.001]
  • [Cites] Dis Colon Rectum. 2001 Nov;44(11):1689-95 [11711743.001]
  • [Cites] Tumori. 2004 May-Jun;90(3):352-5 [15315321.001]
  • [Cites] Can Med Assoc J. 1968 Dec 28;99(25):1259-62 [5700853.001]
  • [Cites] Cancer. 1972 Mar;29(3):670-83 [4551306.001]
  • [Cites] Cancer. 1973 Jan;31(1):241-5 [4683040.001]
  • [Cites] Mayo Clin Proc. 1975 Jun;50(6):317-21 [1127997.001]
  • [Cites] AJR Am J Roentgenol. 1978 Jan;130(1):169-71 [413407.001]
  • [Cites] Am J Clin Pathol. 1978 Jan;69(1):86-90 [619617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1978 Nov-Dec;4(11-12):1045-8 [102620.001]
  • (PMID = 20122250.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] England
  • [Number-of-references] 40
  • [Other-IDs] NLM/ PMC2827478
  •  go-up   go-down






Advertisement